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ABSTRACT 
Mozambique is one of the countries with a high burden of human immunodeficiency virus (HIV), 
hepatitis B virus (HBV) and syphilis. HIV seroprevalence in adults was estimated to be 11.5% in 
2009, syphilis prevalence among women was estimated to be 5.7% in 2010 and an estimated 
national HBV prevalence of above 8%. These infections are sexually transmitted and co-
infections are common. The availability of data on prevalence and incidence of these infections, 
and risk factors related to their spread, is crucial for designing prevention strategies and in order 
to successfully conduct clinical intervention studies. Additionally, a safe, efficacious and 
affordable HIV vaccine would be ideal to better control the HIV epidemic. 
In study I, we prospectively enrolled (n=1380) and followed up a cohort of young adults 
(n=1309, HIV seronegative participants) to determine their suitability for possible participation 
in phase I/II HIV vaccine trials through determination of prevalence and incidence of HIV. We 
also determined the prevalence of HBV and syphilis. The incidence of HIV in this group was 
1.14/100PY. The prevalence of HIV, HBV and syphilis was 5.1%, 12.2% and 0.36%, 
respectively. In study II, we determined the prevalence of HBV seromarkers in 1377 young 
adults in Maputo, Mozambique. The age-specific changes of prevalence of HBsAg and Anti-HBc 
was used to estimate the incidence of HBV using catalytic modelling. The overall prevalence was 
42.8% for exposure to HBV (anti-HBc+), 12.1% for HBV infection (HBsAg+), 8.5% for chronic 
carriers (HBsAg+ and anti-HBc+) and 3.6% for acute infection (HBsAg+ only). The incidence 
of HBV was 180 per 100,000 PY using HBsAg and 2690 per 100,000 PY using anti-HBc. In 
study III, a cross sectional study was conducted at a youth clinic in Maputo, Mozambique, to 
establish, for the first time, clinical laboratory reference values in the country. The hematological 
and biochemistry reference values derived from 257 healthy Mozambican young adults differed 
from those derived from a North American population. In study IV, a phase I trial was conducted 
to assess the safety and immunogenicity of HIV-DNA delivery using the Zetajet ™, a needle-free 
device, in a volume of 0.2 ml (3 mg/ml) intradermally followed by HIV-MVA boosts. The 
volunteers were randomized to receive three immunizations of 600 μg (2 x 0.1 ml, standard 
injection) (n = 10) or 1200 μg (2 x 0.2 ml) (n = 10) of HIV-DNA, followed by two 108 pfu HIV-
MVA boost vaccinations. Four subjects received placebo. After the first HIV-MVA, Env 
responses were significantly higher in the high-dose group compared to the low-dose group 
(median 420 vs. 157.5 SFC/million PBMC, p = 0.014). Preliminary data show that the frequency 
of responders with antibodies against HIV Env antigens in the V2 loop was significantly higher 
in the high-dose group than in the low-dose group, 6/8 (75%) vs. 2/8 (25%), respectively,                   
p = 0.0486. The high dose of HIV-DNA induced the higher average number of Env-reactive 
antigen features in the V2 loop than the low dose. 
Conclusion: The prevalence and incidence of HIV in the youth cohort in Maputo was relatively 
low, suggesting that this group is suitable for recruitment into a phase I/II HIV vaccine trial. The 
prevalence and incidence of HBV was high among young adults in Mozambique. Therefore, 
further HBV prevention strategies should be implemented, including catch-up vaccinations for 
children and adolescents, screening of pregnant women and vaccination of adults at risk of 
exposure. The clinical laboratory reference values established here highlight the need for 
establishing region-specific values for proper patient management and the safe conduct of clinical 
trials in Mozambique. The last study demonstrated that priming with a high dose of HIV-DNA is 
safe and suggests an immunological advantage over the lower HIV-DNA dose. 
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1. INTRODUCTION 
 
1.1. Sexually Transmitted Infections: HIV, syphilis And hepatitis B  
Today, more than thirty pathogens are known to be sexually transmitted. Among them, eight 
are responsible for the majority of the incidence of sexually transmitted infections (STIs). Of 
these eight, four are curable; these are syphilis, gonorrhoea, chlamydia and trichomoniasis. 
Another four are viral infections and are incurable, namely hepatitis B, herpes simplex virus 
(HSV), human immunodeficiency virus (HIV), and human papillomavirus (HPV) (1).  
According to WHO, approximately 1 million people acquired STIs every day worldwide (1). 
Sub-Saharan Africa (SSA) is the epicentre of the HIV epidemic (2), and other STIs are still 
endemic in this region of the world (3). STIs have been associated with many health problems, 
which include cervical cancer, pelvic inflammatory disease, infertility, fetal wastage, ectopic 
pregnancy, and related infant and maternal mortality (4). In addition, STIs such as syphilis and 
herpes simplex type-2 facilitate HIV acquisition (5; 6). Furthermore, HIV has an impact on the 
disease course caused by syphilis (5) and HBV (7), accelerating their progression and making 
them more aggressive. 
In general, STIs are preventable but there are a substantial number of new cases occurring 
worldwide (1). This underscores the need of further improvement of the control of STIs. With 
regard to HIV, there is a clear need of a prophylactic vaccine that can prevent the spread of HIV 
globally and particularly in SSA, where approximately 70% of all HIV infected individuals are 
found. The available methods to prevent HIV infection are dependent on the awareness and 
adherence, which can affect their efficacy (8; 9; 10). HBV infection can be prevented by 
vaccination, but it continues to be a serious health problem, especially in SSA (11), where 
technical, logistical, political and social factors represent a challenge for immunization programs 
(12). 
 In many African countries there is a lack of data on prevalence and incidence of STIs. The 
availability of data on the epidemiology of STIs, and risk factors related to their spread is crucial 
for designing prevention strategies and in order to successfully conduct clinical intervention 
studies.  It is therefore important to make epidemiology data available, and to develop and 
evaluate vaccines, particularly for HIV, to improve the control of these infections in a high 
prevalence setting. 
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1.2. HIV/AIDS 
 
1.2.1. Epidemiology: Global situation 
According to WHO, in 2015 approximately 36.7 million (0.8%) people globally were living 
with HIV, 2.1 million people became newly infected and 1.1 million people died from HIV-
related causes. SSA continues to be the region of the world most affected by HIV, where 25.6 
million people were living with HIV in 2015. SSA was responsible for 70% of the new 
infections that occurred in 2015 (2).   
Globally, the rates of new HIV-1 infections and of deaths related to acquired immune deficiency 
syndrome (AIDS) have declined between 2000 and 2015, by 35% and 28%, respectively, due 
to increased availability of antiretroviral therapy (ART). By the end of 2015, 17 million people 
living with HIV were receiving ART (2), up from 13.6 million in June 2014. In SSA, the HIV-
1 infection rate fell by 41% between 2000 and 2014. The number of deaths related to AIDS in 
SSA declined by 48% between 2004 and 2014. Within the same region, the number of people 
receiving ART increased from 100 000 in 2002 to 10.7 million in 2014 (13). 
 
Figure 1. HIV prevalence in 2015, among adults aged 15-49 years (14).  
 
1.2.2. Epidemiology: HIV/AIDS in Mozambique 
Mozambique has one of the world's highest HIV prevalences (figure 1). Data from the national 
community-based survey (INSIDA) indicated that in 2009, 11.5% of adults aged 15-49 were 
living with HIV in Mozambique, with HIV prevalence being higher among women than men 
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(13.1% vs. 9.2%). For both women and men, the prevalence increases with age until it peaks. 
For women the peak occurs between the ages 25-29 and for men between the ages 35-39. 
Among children aged 0 - 11 years, HIV prevalence is estimated to be 1.4%. Regional prevalence 
varies substantially, estimates range from 3.7% - 9.4% in the northern region, 7% - 15.5% in 
the central area and 8.6% - 25.1% in southern region of the country (15). 
The first case of HIV in Mozambique was reported in 1986 (16).  By 2004, the prevalence of 
HIV among pregnant women was 16%. In 2007, the prevalence was reported to be 13.2%. From 
2009 to 2011, HIV prevalence increased from 13.7% to 15.8% (figure 2). It is possible that the 
increased availability of ART may have contributed to reduction of deaths related to AIDS and 
resulted in an increasing HIV prevalence. Overall, HIV prevalence among pregnant women has 
stabilized in Mozambique, oscillating between 13% and 16% during the period from 2002 to 
2011 (17). 
The rate of new HIV-1 infections in the country declined between 2001 and 2013, from 160 
000 people to 120 000 people, respectively (18). ART may have also contributed to the 
reduction of HIV incidence in the country.  
 
 
Figure 2. Trend of the median overall and regional HIV prevalence in Mozambique, from 2002 
to 2011 (17). 
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1.3. HIV and AIDS 
AIDS is a widespread disease caused by HIV. HIV infects and destroys a variety of human 
cells. The consequence of severe immunologic damage is AIDS, which is characterized   by the 
loss of an effective immune response to specific opportunistic pathogens and tumours (6).  
HIV is part of the Lentivirus family, and it is divided into two types, namely HIV-1 and HIV-
2. HIV-1 is the most common and pathogenic strain of the virus.  HIV-2 causes AIDS with slow 
disease progression and it is largely confined to West Africa. HIV-1 is classified into three sub-
groups: Group M (major), Group O (outlier), and Group N (non-M or O).  Groups O and N are 
restricted to West Africa. Group M, which is the cause of the global HIV pandemic, consists of 
nine subtypes: A–D, F–H, J, and K, and many circulating recombinant forms (CRFs) (6). 
Subtypes A and F can be further divided into sub-subtypes: A1 to A2 and F1 to F2, respectively. 
Subtypes A, B, and C are the most prevalent HIV-1 genetic forms. Subtype C is responsible for 
about 50% of the HIV-1 infections worldwide and it is predominate in southern Africa and India.  
Subtype A is predominant in central and eastern Africa, and in Eastern European countries, while 
subtype B is most frequent in western and central Europe, the Americas, and Australia, and in 
many countries of Southeast Asia, northern Africa, and the Middle East. The CRFs account for 
18% of the HIV infections worldwide, CRF01_AE (previously called subtype E) is predominant 
in Southeast Asia, while CRF02_AG is predominant in West and West Central Africa (19). In 
Mozambique, HIV subtype C is the predominant subtype (20). The enormous genetic diversity 
of HIV-1 may have implications for differential rates of disease progression, emergence of ART 
resistance, and the development of an effective HIV-1 preventive vaccine with broad efficacy 
against all subtypes (19). 
 
1.3.1. Viral structure and replication cycle of HIV 
HIV is a spherical particle with a diameter of approximately 100-120 nm. The virus comprises 
of an envelope that surrounds the nucleocapsid (core), which contains the HIV genome and 
enzymes (reverse transcriptase, protease and integrase). The viral envelope consists of a lipid 
bilayer acquired from the host cell membrane after viral budding and viral glycoproteins (gp) 
(gp120 and gp41). The gp120 is responsible for the attachment of the virus to the host cell and 
the gp41 mediates the cell fusion process. Between the envelope and nucleocapsid lies the p17 
matrix protein. The nucleocapsid is composed of the viral protein p24, typical of lentiviruses 
(Figure 3). The HIV genome consists of two identical 9kb single stranded RNA molecules, 
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which contains nine genes.  Among the nine genes, three are most important for the viral 
replication, namely gag, env and pol. The gag gene encodes proteins of the nucleocapsid, matrix 
and nucleo-proteins. The env gene encodes glycoproteins of the envelope, and the pol gene 
encodes three viral enzymes, namely reverse transcriptase, protease and integrase (21). The 
genome includes six accessory genes, which are: tat, rev, nef, vif, vpr and vpu (for HIV-1) or 
vpx (for HIV-2) (22).  
 
 
Figure 3. Structure of HIV mature virion particles. 
 
 
HIV has an affinity to cells expressing CD4 molecules, such as, T helper lymphocytes, 
monocytes and macrophages, and dendritic cells. (1) The viral gp120 molecules bind tightly to 
CD4 ligand on the host cells resulting in a conformational change in the gp120, exposing the 
chemokine binding domains of gp120 and allowing them to interact with the co-receptor 
CXCR4 or CCR5 on the host cell. Upon interaction between the gp120 and the host chemokine 
receptor, fusion takes place induced by the gp41 protein.  (2) After the fusion, the HIV RNA 
and various enzymes are released into the cell, including reverse transcriptase.  The reverse 
transcriptase commands the transcription of the single-stranded viral RNA genome into a 
double-stranded HIV DNA, which is transported into the cell nucleus. (3) The enzyme integrase 
is responsible for the integration of the proviral HIV DNA into the host’s chromosomal DNA. 
(4) The provirus is transcribed by the host RNA polymerase, resulting in several mRNAs and 
genomic RNA. (5) The mRNAs are translated into viral proteins, which are cleaved by the HIV-
1 protease enzyme. (6) These viral proteins and the replicated viral genomic RNA are 
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assembled and then buds through the cell membrane, producing a mature infectious virus 
(Figure 4) (21). 
 
                                                           
Figure 4. HIV life cycle.  
 
1.3.2. Mode of HIV transmission 
HIV, the cause of the AIDS pandemic, is a result of multiple cross-species transmissions of 
simian immunodeficiency viruses that naturally infect African primates (23). HIV spreads 
through sexual contact, exposure to infected blood and its products, intravenous drug use and 
vertically from mother-to-child (during pregnancy, delivery, or breastfeeding) (21). Sexual 
contact is the most common mode of HIV transmission. Factors, such as high HIV-1 viral load 
and high-risk sexual behaviour including the presence of STIs, having many sexual partners 
and unprotected sex (not using a condom) increase the risk of HIV sexual transmission. Mother-
to-child HIV-1 transmission also plays an important role in the HIV epidemic. In the absence 
of interventions, HIV-1 vertical transmission is estimated to occur at a rate of 25% during 
delivery and 8.9/100 child-years of breastfeeding after the fourth week, with higher rates during 
the first four weeks (6; 21). Sharing unsterilized injection equipment and accidental needlestick 
injuries can be another source of HIV infection (21). An increased risk of HIV-1 transmission 
by stick injuries or vertical mode is also associated with high level of HIV-1 viral load in the 
infected individual (6).  
 7 
In Mozambique, heterosexual transmission of HIV is responsible for the majority of new HIV 
infections in adults. Factors, such as multiple sexual partners, low rate of condom use, mobility 
and migration, sexual intercourse between people of different generations and transactional 
relationships, and low rate of male circumcision drive the epidemic in the country (24). 
 
1.3.3. Diagnosis of HIV infection 
HIV antibody tests are the most commonly used for the diagnosis of HIV infection. However, 
these tests may give false negative results during the window period (between the time of 
infection and production of detectable level of antibodies). Antibodies are usually detectable 
around 3-4 weeks after the infection. HIV testing is usually performed in two phases. First, a 
high sensitivity screening test is performed, and if the outcome is positive a second test with 
high specificity is performed to confirm the result. The enzyme-linked immunosorbent assay 
(ELISA) is the most commonly used for screening purposes and the Western blot procedure as 
a confirmatory test. However, the main disadvantage of the WB assay is related to the high cost 
and the need of skilled people to perform the test. Later generations of ELISAs are able to detect 
the presence of both the antibodies and the viral p24 antigen. These ELISAs reduced the 
window period to almost the levels of the detection of virus RNA, which is about 10-12 days 
after infection (25). Some of the antibody/antigen tests are designed to be rapid HIV tests that 
produce results within 15-30 minutes. The advantage of this test is that they have similar 
accuracy rates to traditional blood tests, while requiring fewer logistics (26).   Other methods 
used for HIV diagnosis include tests that detect the presence of the virus by HIV nucleic acid 
detection, using polymerase chain reaction (PCR) and p24 antigen testing. These tests are able 
to detect early HIV infection before seroconversion. The p24 antigen test detects the viral p24 
antigen in the serum of a HIV infected patient. PCR tests are limitedly used due to the costs and 
the need of skilled staff to perform the test. The qualitative DNA PCR, which allows the detection 
of viral DNA integrated into the host cell’s genomic DNA, is particularly useful for testing infants 
younger than 18 months of age, born from HIV-positive mothers, since HIV antibody assays may 
detect maternal antibodies that these infants carry. Quantitative RNA PCR (viral load), which 
detect plasma viral RNA, is recommended to monitor HIV-positive individuals before or during 
antiretroviral therapy (27). 
The Mozambican national algorithm for HIV testing for adults and infants older than 18 months 
is comprised by two rapid tests, the Determine HIV-1/2 (Inverness Medical, Bedford, United 
Kingdom) as the screening test, followed by the UniGold HIV-1/2 (Trinity Biotech, Bray, Ireland) 
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as the confirmatory test. For individuals with indeterminate results, defined as a reactive 
Determine test followed by a non-reactive UniGold assay, the algorithm is repeated immediately. 
If the result continues to be indeterminate, HIV testing is repeated after 3-4 weeks and if the same 
result is still produced, the algorithm is repeated after 6-8 weeks. Only then, if the result still is 
indeterminate is a venous blood sample collected and sent to the reference laboratory (28) where 
the algorithm is repeated and discordant results are resolved by using PCR.  
 
1.3.4. Prevention of HIV infection 
There are several methods to prevent HIV infections, namely education on HIV, condom use, 
counselling and testing for HIV, ART, pre- and post- exposure prophylaxis, screening of blood 
and its products, prevention and treatment of STIs and medical male circumcision (6). A HIV 
vaccine is not currently available as it is still under development. The combination of the available 
methods has contributed to the reduction of HIV incidence in most countries, but the epidemic 
still not under control and the virus continues to spread at high rates.  This could be because most 
of the available methods are dependent on awareness and adherence (29). Education plays an 
important role in the prevention of HIV infection. Reviews of education on HIV are unanimous, 
in that all programmes targeted at an increase in knowledge about HIV/AIDS, contribute directly 
or indirectly to behaviour change and consequently reduce the risk of infections (30). Condom 
use is essential to prevent HIV transmission (31) and other sexually transmitted infections. The 
perception that condoms reduce sexual pleasure, increase infidelity, that some have an unpleasant 
smell, and its limited availability have been reported to affect its use (32). Counselling and testing 
for HIV have significant benefits. Knowing the HIV status of individuals who are positive can 
result in referral to ART in order to lower the viral load, thereby prolonging life and heath, and 
reducing the risk of HIV transmission to others by 96%. Furthermore, for individuals who have 
negative results, this information can help to reduce high-risk behaviour and continue good health 
(33). ART has also been used for pre- and post-exposure prophylaxis and for prevention of 
mother-to-child HIV-1 transmission (6). Screening of blood and its products is essential in order 
to exclude blood donations at risk of transmitting infection from donors to recipients (34). 
Treating co-infections, such syphilis (5) and herpes simplex type-2 infection, reduce the HIV viral 
load and transmission. Male circumcision is associated with a significantly reduced risk of HIV 
infection and can be used as an additional HIV prevention strategy (6).  
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Mozambique has defined strategies and plans for HIV prevention, which includes all the 
methods mentioned above (24). With these programmes and plans, Mozambique has achieved 
significant progress in the prevention of HIV infections but additional efforts should be made 
in order to control the spread of HIV in the country.  
Despite increasing knowledge about HIV and methods to prevent infections among the 
Mozambican population, the behaviour in relation to HIV has not changed significantly.  The 
INSIDA 2009 survey showed that 67% of females and 76% of males age 15-49 knew of condom 
use as a HIV preventive method. However, only 8% of women and 16% of men used a condom 
at the last time of sexual intercourse (15). The Demographic and Health Survey 2011 found that 
3% of women and 30% of men age 15-49 reported to have had two or more sexual partners in 
the past 12 months. The rates of HIV testing are still very low in the country, and only 45% of 
women and 23% of men age 15-49 have ever been tested for HIV. The levels of stigma and 
discrimination against people infected with HIV are still high in the country, but there is a 
decreasing trend. Additionally, the rate of circumcised men is still low in Mozambique, at around 
47% among men age 15-49 (35).   
ART was introduced in Mozambique in 2003/2004 (24). Subsequently, the number of people 
in antiretroviral treatment increased substantively and by 2012 the coverage among eligible 
patients to ART in country reached 45% (36). Post-exposure prophylaxis is provided for post-
occupational exposure to HIV and for rape victims (37). 
The prevention of mother-to-child transmission program was fully introduced in Mozambique 
in 2006 (38), and as result of the program the number of new infections among children declined 
by 50% or more between 2009 and 2013 (39).  
The HIV Early Infant Diagnosis program, which provides HIV testing for infants younger than 
18 months of age using DNA PCR, was introduced in the country in 2006. This program is 
contributing to the reduction of AIDS related deaths among children by improving the testing 
rates, which result in the early initiation of ART.  
Finally, specific interventions targeting key populations such as men who have sex with men 
(MSM), commercial sex workers (CSW), miners, truck drivers, and others are being designed.   
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1.4. HIV vaccine 
The development of a safe and effective HIV-1 vaccine is critically important to control the spread 
of the virus, since the efficacy of the available methods is dependent on adherence. However, 
despite the urgent need, a HIV vaccine still not available. The reasons why include the genetic 
diversity of the virus, the capacity of the virus to evade adaptive immune responses, the early 
establishment of latent viral reservoirs, the difficulty in the development of antigens that are able 
to induce broadly reactive antibody responses, uncertainty about what constitutes protective 
immunity (40) and the absence of appropriate animal models (41). 
Several progressions in the development of a HIV vaccine have been made. Studies in animals 
have demonstrated that vaccine regimens expressing the simian immunodeficiency virus (SIV) 
Gag, Pol and Env antigens conferred protection against acquisition of SIV infection and that Env 
was crucial for the protective effect of the vaccine (42; 43). Animal models have also suggested 
that Env-specific antibodies are essential for blocking virus acquisition (43) and Gag-specific 
cellular immune response for the control of viremia (42) in the vaccinated monkeys. 
Unfortunately, the vaccine designs used in pre-clinical trials, which had shown efficacy, did not 
produce the same result in humans (44; 45). However, they have contributed valuable information 
for the development of a HIV vaccine. Studies on humans indicate that T cytotoxic cells (CD8+ 
T cells) and CD4+ T cells can mediate control of viral replication in the HIV infected individual 
(46; 47). The results from animal models and studies on humans indicate that both humoral and 
cell-mediated HIV-specific immune responses would be important protective factors against HIV 
infection. Based on these suggestions, the majority of vaccine candidates that are being produced 
for use in clinical trials, aim to induce both antibody-mediated and cell-mediated HIV-specific 
immune responses. Despite more than 180 clinical trials conducted, HIV-1 vaccine development 
efforts, to have a prophylactic or therapeutic vaccine, have not yet proven successful. Six HIV 
vaccine efficacy trials (phase IIb and III) have been conducted but only one, the RV144 phase III 
trial in Thailand, showed protective efficacy, about 60% at 12 months (48) and 31% at 42 months, 
after completion of the vaccine series (49). The results from this trial are guiding the research on 
HIV vaccine today.  
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1.4.1. HIV-1 Vaccine Strategies 
Viral infections have been successfully controlled by vaccines based on the live attenuated 
viruses, whole killed viruses and protein subunits. In the search for a HIV vaccine, live attenuated 
virus vaccines have been tested in the SIV/macaque model and have showed substantial 
protective efficacy against SIV challenges in rhesus monkeys. However, these approaches are not 
being considered for HIV-1 due to significant safety concerns. The utility of whole killed viruses 
and protein subunits is limited, due to their inability to induce broadly reactive neutralizing 
antibody (NAb) responses and by their inability to elicit CD8+ T lymphocyte responses. For HIV-
1, novel vaccine strategies are being used. These strategies include gene delivery technologies, 
such as plasmid DNA vaccines and live recombinant vectors that are engineered to express HIV-
1 antigens (40). DNA vaccines have been shown to induce predominantly T cell responses that 
were able to control viral replication and delay T CD4+ cells decline in vaccinated macaques 
challenged with SIV (50; 51; 52).  Multiple injections of high doses of DNA vaccines are typically 
required to elicit detectable immune responses in nonhuman primates and humans. Therefore, 
research continues on the development of adjuvants for DNA vaccines and improved delivery 
technologies, to improve DNA immunogenicity (40).  Adjuvants such as IL-12, IL-15 and 
granulocyte macrophage colony-stimulating factor (GM-CSF) (53), and methods such as in vivo 
electroporation (40) and needle-free injection devices to deliver DNA vaccine have been shown 
to enhance the immunogenicity (54). Live recombinant vectors are used alone or in context of 
boosting the responses induced by DNA vaccines. The most commonly used viral vectors are 
adenoviruses and poxviruses (40).  Prime-boost vaccination regimen using DNA priming and 
recombinant virus based vaccines, such as recombinant modified vaccinia virus Ankara (MVA) 
for boosting, has been shown to induce broad and strong HIV-specific T cell responses (54; 55) 
and also elicited HIV-specific binding antibodies (56) and functional antibodies (57). Live 
recombinant virus prime-protein boost, or DNA prime-protein boost are other HIV vaccine 
strategies used (58). The RV144 trial used a recombinant avipoxvirus vaccine boosted with HIV 
Env protein (49).  
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1.4.2. Lessons learnt from HIV vaccine phase IIb and III trials 
Four HIV-vaccine candidates were tested in six efficacy trials. The first two efficacy trials (phase 
III) Vax003 and Vax004 used bivalent vaccines containing the monomeric gp120 alone from 
subtype B/E and subtype B, respectively, and aimed to induce humoral responses. The vaccine 
failed to prevent HIV-1 acquisition infection or delay disease progression. The vaccine generated 
higher level of NAb against an easily neutralizable virus (HIV-1 MN) and this was correlated 
with lower risk of HIV infection. Lower levels of NAb were induced against viruses that were 
difficult to neutralize and this was not correlated with protection, suggesting that the titers and 
breadth of response were not sufficient. The HVTN 502 phase IIb (Step) and HVTN 503 phase 
III (Phambili) trials tested the Merck recombinant Ad5 gag/pol/nef subtype B and aimed to induce 
specific cell-mediated immune responses. In both studies, the vaccine was able to generate T cell 
immune responses, but did not prevent HIV-1 infection and there was increased risk of HIV 
acquisition in vaccinees compared to placebo recipients. In the Step trial, the risk of HIV-1 
infection was significantly lower in men with no pre-existent immunity to Ad5 and who were 
circumcised (59; 60). The Thai RV144 phase III clinical trial tested a recombinant avipoxvirus 
vaccine boosted with HIV Env protein, aimed to induce both cellular and humoral immune 
responses. The trial showed a modest efficacy of 31.2%; although the vaccination did not have 
effect on the HIV viral load and T CD4 count in the infected subjects (49). In this trial binding 
IgG antibodies to variable regions 1 and 2 of HIV-1 envelope proteins were inversely correlated 
with the risk for HIV-1 infection, while HIV-1 Env-specific plasma IgA responses directly 
correlated with risk (61). The HIV-specific T cell response in the RV144 vaccinees, although 
modest in frequency compared with humoral immune responses, confirmed HIV gag120 V2 
specificity, polyfunctionality and functional cytolytic capacity (62).  HVTN 505 (phase IIb) is the 
sixth trial. This study tested gag/pol/env subtype A/B/C DNA prime boosted with rAd5 vector 
and also aimed to induce cellular and humoral immune responses. This trial showed no efficacy 
on HIV acquisition, viremia control and CD4 count (59). 
The results of these trials suggest that a HIV vaccine is feasible, but innovation to improve 
immunogens and vaccine strategies is needed. Additionally, clarification of what constitutes 
protective immunity is also required. 
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1.4.3. Challenges in conducting a HIV vaccine clinical trial 
For conducting clinical studies, a well-organized and experienced regulatory authority is needed 
in the country where the study is to be conducted.  In developing countries, ethical approval 
processes are often lengthy or not well defined, and there is significant bureaucracy and a lack of 
regulatory staff with expertise in reviewing. This considerably delays the start of the trials (63). 
Conducting a clinical trial demands qualified human resources, infrastructure (clinic facilities, 
laboratory facilities and data management facilities), and an appropriate population for the study. 
Clinic facilities are the places where researchers interact with participants for information 
exchange, counselling sessions, physical exams, and where the vaccine candidate can be injected. 
Laboratory facilities for clinical trials can be divided into two categories. One is small and is 
located near the clinic, so that samples can be collected for processing in order to confirm the 
eligibility of participants. The second category of laboratory facility is more sophisticated and it 
is responsible for the immunogenicity testing, for example, performing assays to find antibody 
and cell-mediated immune responses. In addition, data management facilities are required to 
record the data of ongoing trials, generate reports on study outcomes and archive documents from 
the study according to good clinical practice guidelines. It is also important to select the 
appropriate population for the study. Phase I and II trials provide information on the safety of the 
candidate vaccines and the ability to induce immune responses. For these early phases of vaccine 
evaluation, healthy volunteers with low-risk for HIV infections are sought. In phase IIb and III 
trials where the aim is to see if the vaccine is effective, a high-risk population is involved (64). 
Understanding the targeted population is important to enable high retention. 
Finally, it is indispensable to have local clinical laboratory reference values to assess participant 
eligibility and safety of the product. The use of improper reference values in clinical trials may 
result in unnecessary exclusion of eligible participants, which can affect the time period of trial 
enrolment, due to the large number of participants that must be screened in order to reach the 
target sample size. A long enrolment period impacts on both workload and study cost. The use of 
non-local derived values may also contribute to over-reporting of adverse events (AEs) (65). 
Laboratory abnormalities based on non-indigenous laboratory reference values and medical 
abnormalities were reported to be the main reasons for exclusion of volunteers from two Kenyan 
HIV vaccine clinical trials (66). Moreover, studies have suggested that use of the US NIH 
Division of AIDS (DAIDS) toxicity tables may not be appropriate for African populations (65; 
67).  
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1.5. Syphilis 
 
1.5.1. Epidemiology  
 
Syphilis remains a global health problem and it is to a higher degree affecting developing 
countries. WHO estimated that there were 10.6 million new syphilis cases in adults worldwide in 
2008, of which an estimated 3.4 million cases occurred in Africa, 3.0 million in South-East Asia 
and 2.8 million in the Americas (68). In the WHO region of the Americas, Latin America and the 
Caribbean are the most affected (3). In North America and Western Europe the incidence of 
syphilis is low, 5.3 per 100 000 in 2013 (69) and 4.4 per 100,000 in 2010 (70), respectively. 
However, increasing rates of syphilis have been reported in North America and in many countries 
in Europe (69; 70). 
For Mozambique, WHO reported a syphilis prevalence of 5.7% among women attending 
antenatal services in 2010 (71). In different parts of the country, syphilis prevalence among 
pregnant woman in 2009 was 5.8%, 2.0%, and 1.8% in northern, central and southern regions, 
respectively (16). Data from WHO indicates a trend of decline in rates of syphilis in Mozambique, 
from 7.9 % in 2008, 6.9% in 2009 to 5.7% in 2010 but the rate of infections is still high (72).  
 
Figure 5. Global prevalence of syphilis among pregnant women (73).  
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1.5.2. Etiology, Transmission, pathogenesis and clinical features 
 
Syphilis is a sexually transmitted infection caused by the bacteria Treponema pallidum 
subspecies pallidum. Treponema pallidum belongs to the order Spirochaetales, family 
Spirochaetaceae and genus Treponema (74). 
 
Humans are the only known source of treponemal infection. Transmission mainly occurs by 
sexual contact or through the placenta to the foetus. Syphilis can also be transmitted by kissing, 
blood transfusion and accidental inoculation. The bacteria can penetrate thought microscopic 
skin lesions or mucous membranes (74; 75).  
The pathogenesis of syphilis appears to be a result of the invasive properties of Treponema 
pallidum. This bacteria has the ability to invade intercellular junctions of endothelial cell 
monolayers and intact membranes, causing the clinical complications of syphilis (74; 75). 
 
Syphilis has four clinical stages of infection, which are primary, secondary, latent, and tertiary, 
and may also occur congenitally. The primary syphilis is typically a single chancre, which 
appears at the site of inoculation, after an incubation period of 3 to 90 days.  The primary 
syphilis disappears spontaneously after few weeks (74). In the secondary syphilis, the most 
common symptom is a disseminated mucocutaneous rash. Other symptoms may include sore 
throat, muscle aches, malaise and weight loss. These symptoms usually occur within 12 weeks 
after initial inoculation and usually resolve spontaneously (75). The period from disappearance 
of the secondary syphilis until tertiary manifestations appear, which can last for years, is called 
latent or asymptomatic syphilis. In tertiary syphilis there are gummas (granulomatous lesions), 
neurological, or cardiovascular symptoms. Congenital Syphilis can cause adverse outcomes in 
pregnancy, resulting in spontaneous abortion, stillbirth, premature delivery, perinatal death, 
hydrops fetalis and low birth weight (74). 
 
1.5.3. Clinical course of Syphilis and HIV Co-infection 
 
The clinical manifestations of syphilis and the disease course may be altered in the presence of 
HIV. Syphilis may be more aggressive and the latency period may be decreased in co-infection 
with HIV (5). In HIV infected patients, the primary syphilis is more likely to be asymptomatic 
but it may also consist of multiple chancres as well as large and deeper lesions. HIV infected 
patients are more likely to present secondary syphilis, which is often more aggressive and 
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present with atypical clinical manifestations (5; 76). Moreover, patients co-infected with HIV 
and syphilis are more likely to have neurosyphilis (5; 76; 77) and cardiovascular diseases (77). 
Syphilis has an impact on the acquisition of HIV infection. Genital ulcers caused by syphilis 
increase the risk for HIV acquisition by facilitating the entrance of the virus into systemic 
circulation and increasing the number of cells receptive to HIV or increasing the expression of 
cell receptors (5). There is controversy regarding the effect of syphilis on the course of HIV 
infection.  Multiple studies have suggested that syphilis can negatively affect CD4 cell counts 
and increase HIV replication (78; 79; 80), while others did not find any impact on HIV-1 disease 
progression (81). Syphilis may have a transient impact on the level of HIV viral load and CD4 
count in some patients, which is resolved after treatment of the treponemal infection  (82). 
 
1.5.4. Syphilis Diagnosis  
 
Indirect diagnoses (serological test of syphilis - STS) are most commonly used for syphilis 
diagnosis, regardless of the stage of the disease.  However, these tests may be negative in early 
primary syphilis and the direct identification of the bacteria by dark field microscopic (DFM-TP) 
or direct immunofluorescent antibody test (DFA-TP) of lesion exudates and tissues, and nucleic 
acid amplification methods such as polymerase chain reaction (PCR) may be useful to confirm 
the diagnosis. The limitation of the direct diagnosis of Treponema pallidum is basically related to 
the cost and the need of skilled people to perform the tests (83). 
The STS are based on the detection of antibodies and they are divided into non-treponemal and 
treponemal tests. The nontreponemal tests, such as the Venereal disease research laboratory 
(VDRL) test and the Rapid Plasma Reagin (RPR) card test, are used as a screening tests and they 
detect IgM and IgG antibodies against cardiolipin that is present in the sera of patients with 
syphilis, but can also occur in response to a variety of conditions unrelated to syphilis. The 
treponemal tests detect antibodies that specifically target the treponema. Treponema-specific 
antibodies remain even after clearance of infection. Therefore, they are used as confirmatory tests 
to verify reactivity in nontreponemal tests. Treponemal tests include the fluorescent treponemal 
antibody-absorbed test (FTA-ABS), Treponema pallidum hemaglutination assay (TPHA), 
Treponema pallidum particle agglutination (TPPA) and enzyme immunoassay (EIA) (83; 84).  
In general, STS are used for screening in both HIV-negative and positive individuals. However, 
in some cases HIV infection may modify the result of the STS. HIV may cause polyclonal B cell 
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activation with increased levels of immunoglobulins, which could lead to the positive STS even 
after elimination of Treponema pallidum. HIV infection can also depress B cell functions, which 
may lead to false negative results in STS. Thus, when clinical findings are suggestive of syphilis 
and STS are negative, it is recommended to use other tests, such as DFM-TP and DFA-TP using 
biopsy samples of the lesion, and PCR (5). 
 
1.6. Hepatitis B  
 
1.6.1. Epidemiology  
 
The prevalence of chronic HBV infection varies greatly in the world (Figure 6). There are 
regions of high, intermediate and low endemicity, as defined below: 
High endemicity: regions where ≥ 8% of the population is infected, which include most 
developing areas, such as South East Asia, China, sub-Saharan Africa and the Amazon Basin. 
Intermediate endemicity: regions where 2-7% of the population is infected, which include 
part of Eastern and Southern Europe, the Middle East, Japan, and part of South America.  
Low endemicity: regions where < 2% of the population is infected, which include most 
developed areas, such as North America, Northern and Western Europe and Australia (85).  
According to WHO, 240 million people are chronically infected with HBV and about 686 000 
people die annually due to HBV clinical complications (2).  
United States of America and Europe are low endemic regions. The USA has an estimation of           
0.8–1.4 million of people living with chronic HBV infection, of which 70% were born in countries 
from high and intermediate endemicity regions (69). In Europe, WHO estimated an overall 
prevalence of 1.8% HBV carriers among adults in 2013. However, the epidemiology of hepatitis 
B in the Europe is diverse, the prevalence varies from extremely low (< 0.1% in Hungary) to high 
(13% in Uzbekistan) (86). 
In sub-Saharan Africa, the prevalence of HBV varies from 9-20% (87). For Mozambique, 
studies have estimated a prevalence of 8.34% to 14.6% in the general population (88; 87), 6.0% 
to 20.5% in blood donors (89; 90; 91) and 8% among women from a rural area of southern 
Mozambique (92). 
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Figure 6: Geographic distribution of chronic hepatitis B infection (93).  
 
1.6.2. HBV and HCC 
 
Only about one-third of adults with acute HBV infection develop clinical symptoms and signs 
of hepatitis, which include fatigue, nausea, jaundice, and in rare cases, acute liver failure. The 
clinical incubation period of acute HBV infection ranges from 30–180 days after exposure (94). 
Chronic infection with the hepatitis B virus has been associated with hepatocellular carcinoma 
(HCC) development. In Africa and East Asia, 60% of HCC has been attributed to hepatitis B 
and in the developed western world; approximately 20% of cases can be attributed to HBV 
infection (95). The risk of developing HCC is 100 times higher in patients with persistent HBV 
infection compared to non-infected individuals (96; 85). Other risk factors for HCC include 
cirrhosis, alcoholism and inherited conditions such as hemochromatosis and alpha-1-antitrypsin 
deficiency (95). 
HBV has eight genotypes (A-H), which were classified based on the divergence of ≥ 8% of the 
entire genome.  The HBV genotypes have distinct geographical distribution as summarized in 
table 1. Several studies suggested that HBV genotypes may influence the clinical outcome of 
 19 
the HBV infection (85). For example, in Taiwan genotype C has been reported to induce HCC 
much later than genotype B. However, genotype C is linked to more severe liver disease 
including cirrhosis and HCC, whereas genotype B is associated with HCC in non-cirrhotic 
patients. In relation to treatment, it was demonstrated that genotype C has a lower response to 
interferon therapy compared to genotype B (97). Another study conducted in Europe showed 
that genotype A responds better to interferon treatment than other HBV genotypes (85).   
The pathogenesis of HBV in HCC may be a direct or indirect effect of the virus. The indirect 
effects include the process of the inflammation, regeneration and fibrosis associated with 
cirrhosis due to the HBV infection (95). HBV DNA has been shown to become integrated into 
the DNA of infected hepatocytes. The insertion of HBV DNA into host genome can create an 
unstable environment, which may induce genomic alterations or may lead to the production of 
altered protein products; these events can facilitate hepatocyte malignant transformation. In 
addition, the expression of HBV proteins such as surface proteins and the X protein (HBx) may 
have direct effect on cellular functions, leading to the tumour formation (98).   
 
Table 1: Geographic distribution of HBV genotypes. Adapted from ref. (85). 
 
 
1.6.3. Clinical course of HBV and HIV co-infection  
In general, HBV tends to be more aggressive in HIV infected patients than in HIV uninfected 
patients. HIV infected patients have higher rate of HCC than HIV uninfected patients. HIV 
infection alters the course of chronic hepatitis B infection by increasing serum HBV DNA 
concentrations, declining levels of liver enzymes and faster development of liver cirrhosis, 
Distributions Genotypes 
White Caucasians in Europe, Black Americans in US (Ae), Black Africans in 
South Africa (Aa), Asia (Aa), India 
A (Aa, Ae) 
Southern China (Ba), Taiwan (Ba), Vietnam (Ba), Asians in the USA, Japan (Bj) B (Ba, Bj) 
China (Mainland and Taiwan), Japan, Thailand, Asians in the USA C 
White Caucasians (Southern Europe), Arabs (North Africa and the Middle East), 
India 
D 
West Africa E 
Central and South America F 
United States, France G 
Central America H 
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particularly in patients with low CD4 T cell counts. Low CD4 T cell counts decrease the 
inflammatory response to chronic hepatitis B (7).  The consequences of HIV and HBV co-
infection can also include the effects of the HIV antiretroviral treatment in the disease course 
caused by HBV.  Studies from Thailand and Taiwan showed that HIV and HBV co-infection 
increases the risk of hepatotoxicity from antiretroviral drugs by three to five times. Another 
issue, the interruptions or changes in HIV ART, can cause emergence of drug-resistant HBV. 
Furthermore, HIV ART may cause exacerbation of chronic hepatitis during immune restoration 
(99). 
Controversy exists with regard to the impact of HBV on the disease course caused by HIV. 
Some studies have suggested that HBV can negatively affect the recovery of CD4+ T cells in 
HIV infected patients (100) while others did not find any impact on CD4+ T cells depletion and 
progression to AIDS (101). 
 
1.6.4. Viral Structure and replication cycle of HBV 
 
The HBV particle is a spherical enveloped DNA virus with a diameter of 42 nm, which belongs 
to the Hepadnaviridae family.  The viral particle consists of a lipid bilayer envelope containing 
HBsAg, which surrounds the nucleocapsid core (HBcAg). The nucleocapsid core contains the 
viral DNA genome and enzymes used in viral replication (DNA polymerase) (figure 7). The 
genome of HBV is a partially double-stranded circular DNA of about 3.2 kilobase (kb) pairs. It 
is organized in a compact manner with four overlapping open reading frames (ORFs), namely 
S, C, P, and X. The S ORF encodes the viral surface envelope proteins (HBsAg). The C ORF 
encodes the viral nucleocapsid core (HBcAg) or hepatitis B e antigen (HBeAg), depending on 
whether translation is initiated from the core or precore regions of the C genes. P and X ORFs 
encode the DNA polymerase and a 16.5-kd protein (HBxAg) with multiple functions (signal 
transduction, transcriptional activation, DNA repair, and inhibition), respectively (Figure 8).  
The DNA polymerase is functionally divided into three domains: the terminal protein domain, 
the reverse transcriptase (RT) domain and the ribonuclease H domain, which are involved in 
encapsidation and initiation of minus-strand synthesis, catalyzes genome synthesis, and 
degrades pregenomic RNA and facilitates replication, respectively (94). 
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 Figure 7: Structure of HBV mature virion particles.  
        
 
 
 
 
 
 
Figure 8: The organization of HBV genome, key regulatory elements and RNAs. Reprinted 
with permission from (94). 
 
Hepatocytes are the only confirmed site for HBV replication (102). The HBV virions, likely 
using the pre-S domain of the surface protein, bind to unknown hepatocyte surface receptors. 
Following the binding of the virus to the host cells, fusion takes place which results in the 
release of the viral cores into the cytoplasm. The viral cores are transported into the nucleus 
where the virus DNA turns into a covalently closed circular form (cccDNA). The cccDNA is 
transcribed by the host RNA polymerase to produce all viral RNAs necessary for protein 
production and viral replication. The viral RNAs are transported out to the cytoplasm and then 
are translated into different viral proteins. Core particles are then assembled in the cytosol with 
a single pregenomic RNA and viral DNA polymerase packed with core proteins. The viral 
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genome is then synthetized by reverse transcription of the pregenomic RNA.  A large proportion 
of the core’s particles are coated with viral lipoprotein envelopes and the virion assembly is 
exported from the cell as a mature infectious virus, while a small portion of core particles are 
sent back to the nucleus to maintain a stable pool of the cccDNA (figure 9). The integration of 
the viral genome into the host genome is not necessary for the HBV replication (98).   
 
Figure 9. HBV life cycle. Reprinted with permission from (94). 
 
1.6.5. Mode of HBV transmission 
 
Humans are the only natural host of HBV. HBV is spread through contact with infected blood 
and other body fluids. In high endemicity areas, the most common route of transmission is 
perinatal during pregnancy or horizontal in early childhood, particularly in China and Southeast 
Asia, and sub-Saharan Africa, respectively. In intermediate endemicity areas HBV transmission 
is either perinatal or horizontal (103) and occur in all age groups (85).  In low endemicity areas, 
HBV is acquired by horizontal transmission during adolescence or adulthood (103), in well-
defined high-risk groups, which include sex workers and homosexual males, injection drug 
users, health care workers, and patients submitted to regular blood transfusions (85). The risk 
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of HBV acquisition through blood transfusion has been greatly reduced due to the improvement 
of diagnostic tests and progressively broader screening for HBV infection (103; 85). 
 
1.6.6. Diagnosis of HBV infection 
 
The diagnosis of HBV infection is based on serological testing for the detection of antibodies 
and antigens. Serologic tests are commercially available for all markers except HBcAg because 
no free HBcAg circulates in blood. 
On-going HBV infection is diagnostic by the presence of HBsAg. Acute infection is identified 
by the presence of HBsAg only, since this is the only serologic marker detected during the first 
3–5 weeks after infection. HBeAg can be detected in acute or chronic HBV infection. The 
presence of HBeAg indicates a high level of virus replication and high degree of infectivity.Life 
exposure to HBV (present or past HBV infection) is identified by the detection of total Anti-
HBc in serum using assays that detect IgM and IgG class antibodies. The presence of the IgM 
class of anti-HBc in serum is an indication of acute HBV infection. Chronic HBV infection is 
diagnostic by the detection of HBsAg and total anti-HBc (93).  
HBV DNA assays are available and they are useful for quantifying the HBV viral load and 
monitoring response to treatment (104). 
 
1.6.7. Prevention of HBV infection 
 
The main strategies available for the prevention of HBV infection are: behaviour modification, 
passive immunoprophylaxis and active immunization (85). 
Behaviour modification, which includes changes in sexual practice and screening of blood 
products, has reduced the risk of HBV infection. However, this strategy has a greater impact in 
developed countries than in developing countries, where HBV transmission mainly occurs in 
neonates and children in early childhood. In these age groups, passive and active 
immunoprophylaxis will be more effective (85). Additionally, HBV screening in pregnant 
women should be introduced in developing countries to reduce the risk of HBV mother-to-child 
transmission.  
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Passive immunoprophylaxis is used in four situations: (1) new-borns of HBV infected mothers, 
(2) after needlestick exposure, (3) after sexual exposure, and (4) after liver transplantation. 
Immunoprophylaxis is recommended for all infants born from HBV infected mothers. The 
current dosing recommendation is 0.13 ml/kg HBIG within 12 hours after birth in combination 
with active immunization. The combination results a 90% level of protection against HBV 
perinatal acquisition (85). 
Active immunization through the HBV vaccine is recommended by WHO, to be included in 
national immunization systems in countries with an HBV prevalence ≥ 8% (85). By 2015, 184 
countries had routine infant immunization with the HBV vaccine and the global coverage with 
3 doses of the vaccine was estimated at 83% (105). The complete vaccination induces protective 
antibody levels in more than 95% of infants, children and young adults. Protection lasts for at 
least 20 years (11). There are still challenges in order to achieve the goal of universal childhood 
immunization against HBV, such as poor immunization delivery infrastructure, low coverage 
and limited financial resources. Therefore, efforts are still needed to improve the global HBV 
vaccination coverage (85). 
 The strategy of prevention of HBV infections in Mozambique is based on the national 
vaccination program, which administrates the HBV vaccine to infants at 2, 3 and 4 months of age 
(106). Behavioural change is one of the targets of the Mozambique government to prevent STIs.  
  
 
 
 
 
 
 
 
 
 
 25 
2. RATIONALE OF THE STUDY 
 
There is consensus that HIV, HBV and syphilis are global health problems, especially in Sub-
Saharan Africa, including Mozambique. These infections are sexually transmitted and co-
infections are common. The presence of syphilis has been implicated as a risk factor for the 
acquisition of HIV infections. Syphilis infection may also accelerate the progression to AIDS. 
Therefore, preventing syphilis infections would contribute to the reduction of HIV transmission 
or to improve the lives of HIV-infected patients, slowing the progression to AIDS. On the other 
hand, HIV infection has an impact on the disease course caused by syphilis and HBV infections. 
Since HIV is one of the major health problems in Mozambique, it is important to prevent more 
people from becoming infected with HIV, and also protect the general population, and 
especially preventing HIV infected patients from acquiring syphilis and HBV infections. 
However, despite the fact that they are preventable infections, especially HBV infections, since 
a prophylactic vaccine is available, they remain a serious health issue in the country. 
Although HIV prevalence is well documented in Mozambique, there is a lack of information 
on HIV incidence and risk factors associated with infections of virus among the young 
population, the age group where most of the transmissions occur. Furthermore, despite the 
magnitude of HBV prevalence in Africa and the world at large, there is no information available 
on the magnitude of HBV infection and risk factors related to its spread in unvaccinated young 
adults in Mozambique. HIV co-infection with HBV or syphilis among the youth is also poorly 
documented in Mozambique.  Therefore, the first two studies of this project were performed to 
provide data on prevalence and/or incidence of these infections, and risk factors related to their 
spread, which may be useful for designing prevention strategies and for conducting successful 
clinical intervention studies.  
Clinical laboratory reference values may differ significantly between populations and 
Mozambique, as in many African countries, is still using values derived from populations living 
in Europe and North America, due to the absence of locally derived values. Therefore, there is 
a need for studies that establish local reference values and analyse the impacts of using values 
derived from other populations in Mozambique for patient management, and in clinical studies.  
In study III, we established for the first time, normal laboratory values in Mozambique. 
 Many infectious diseases have been successfully controlled by the use of vaccines. This is 
likely to also be true for HIV, since the available prevention methods are insufficient in 
 26 
controlling the spread of this virus. Therefore, there is a need to keep searching for a safe, 
efficacious and affordable vaccine that can control the spread of HIV. The HIVIS and TaMoVac 
01 Tanzania trials, which used a HIV-DNA prime and HIV-MVA boost strategy showed strong 
and broad immune response. In the HIVIS trials the HIV-DNA vaccine was administrated using 
the Bioject needle-free device, in a dose of 1000 μg per immunization given as 5 injections of 
0.1 ml and separating Env and Gag plasmid pools. The TaMoVac 01 study performed in 
Tanzania, assessed the possibility of simplifying the regime used in the HIVIS studies to 2 
injections, using separated and combined plasmids. However, the maximum dose that could be 
delivered intradermally with the Bioject in 2 injections was 600 μg, since this device can only 
contain 0.1 ml while the highest concentration of HIV-DNA available was 3 mg/ml.  Therefore, 
a rigorous comparison of 2 vs. 5 injections could not be made. In study IV, we explored the 
safety, tolerability and immunogenicity of delivering the HIV-DNA vaccine at a concentration 
of 3 mg/ml, in a volume of 0.2 ml, using a needle free device, the ZetajetTM. We compared 
priming with HIV DNA at a total dose of 600 µg (2 x 0.1 mL of 3 mg/ml) with a higher dose 
of 1200 µg (2 x 0.2 ml of 3 mg/ml). Boosting vaccinations were performed using HIV-MVA 
delivered intramuscularly. This was the first study to assess DNA delivery using ZetajetTM, in a 
volume of 0.2 ml. This study also aimed to build capacity for conducting clinical trials and 
establish, on site, methods to assess the immunogenicity of vaccine candidates.  
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3. AIM AND OBJECTIVES 
 
General Aims 
The primary aim of this project was to improve the control of sexually transmitted infections 
in a high prevalence region. The secondary aim was to establish a laboratory framework for 
conducting HIV vaccine trials, and to monitor and characterize cellular and humoral immune 
responses induced by a HIV candidate vaccine in Mozambique. 
Specific objectives 
Paper I: To establish a youth cohort in Maputo, Mozambique, define the incidence of 
HIV and prevalence of HIV, HBV and syphilis in the group, and assess the 
suitability of the cohort for possible participation in phase I/II HIV vaccine 
trials. 
 
Paper II: To determine the prevalence and incidence of HBV, the prevalence of 
exposure, the proportion of chronic carriers and the rates of HBsAg 
seroclearance in unvaccinated sexually active young adults in Maputo, 
Mozambique and assess the risk factors associated with HBV infections in the 
group. 
 
Paper III: To establish reference values for immunology, hematology and chemistry 
parameters in individuals between 18-24 years old in Maputo, Mozambique 
and to assess the potential implication of the study derived values in clinical 
trials.  
 
Paper IV: To compare the safety, tolerability and immunogenicity of delivering HIV-
DNA intradermally at a total dose of 600 µg (2 x 0.1 ml of 3 mg/ml) vs. 1200 
µg (2 x 0.2 ml of 3 mg/ml) using a needle-free device, the ZetaJet™ followed 
by two HIV-MVA boosts delivered intramuscularly in healthy Mozambican 
young adults.  
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4. METHODS 
 
Table 2. Summary of the study designs used in this thesis. 
 
 
4.1. Paper I, II and III: Studies Related to the Maputo youth cohort 
 
4.1.1. Study design and population 
In preparation for a phase I HIV vaccine trial (TaMoVac 01) in Mozambique (paper IV), we 
performed a study to define the prevalence and incidence of HIV and other sexually transmitted 
infections in Maputo, in a population of young adults (paper I). The study took place at the youth 
clinic of Maputo Central Hospital, between August 2009 and October 2011. In this study, a total 
of 1380 youths between 18-24 years old, of both genders (1060 females   and 320 males), were 
Paper Research question Design 
 
I 
Is a youth cohort in Maputo suitable for 
a phase I/II HIV vaccine trial?  
A suitable cohort should have low 
prevalence and incidence of HIV, and 
low prevalence of other STIs. The cohort 
should also have low sexual risk 
behaviours and good retention rate. 
Cohort study: Young adults attended at a 
youth clinic in Maputo, Mozambique. 
 N = 1380 
 
II 
What is the prevalence of HBV markers, 
incidence of HBV and risk factors for 
HBV infections in Mozambican 
unvaccinated sexually active young 
adults? 
Cross-sectional study: Young adults 
recruited from the cohort mentioned above.  
N = 1377 
 
III 
Are the laboratory reference values 
derived from Mozambican young adults 
similar to those from European or 
American population? 
Cross-sectional study: Young adults 
recruited from the cohort mentioned above. 
 N = 257 
 
IV 
Will the high dose (1200 µg) of HIV-
DNA vaccine have an effect on safety 
and immunogenicity? 
Randomized double-blinded placebo 
controlled study:  Young adults recruited 
from the cohort mentioned above. N = 24 
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consecutively enrolled. At baseline, socio-demographic data, and at each visit, behavioural 
characteristics and clinical history were recorded using a structured questionnaire followed by a 
physical examination. HIV, HBV and syphilis tests were performed before enrolment. 
Participants with negative or indeterminate HIV test results were enrolled in the longitudinal 
study for determination of HIV incidence.  The participants were asked to visit the study site 
every 4 months during one year. At all visits, dried blood spots (DBS) were collected from the 
subjects with negative or indeterminate HIV test results and stored for future testing.  Pre- and 
post-test HIV counselling, STI risk reduction counselling and condoms were provided at all study 
visits. During the study, STI detection and treatment, or referral to another unit was provided for 
those who needed. CD4+ T-cells count and HIV-1 viral load were performed in all HIV infected 
participants on the day of diagnosis.  
We also determined the prevalence of HBV markers and incidence of HBV in the cohort, and 
accessed risk factors for HBV infection in this group. In this sub-study, 1377 participants were 
screened for HBV seromarkers (paper II). Additionally, we established clinical laboratory 
reference values for this age group using blood sample from 257 healthy individuals (149 females 
and 108 males) recruited from the same cohort. Only volunteers that were HIV, HBV and syphilis 
negative and non-pregnant women were enrolled in this cross sectional study (paper III). 
 
4.1.2. Laboratory methods 
HIV testing (Study I and II) and determination of incident cases (Study I) 
HIV diagnosis was performed using the Determine HIV-1/2 (Inverness Medical, Bedford, United 
Kingdom) as a screening test, followed by the UniGold HIV-1/2 (Trinity Biotech, Bray, Ireland) 
as a confirmatory test. We considered as HIV infected individual who were reactive in both 
assays. Discordant results were defined as indeterminate. To determine the timing of HIV 
infection in a subject, a reactive HIV rapid assay was performed on a follow-up visit, where the 
DBS samples collected from the previous visits were tested using DNA PCR (Roche Amplicor 
HIV-1 DNA test, version 1.5, Roche Molecular Diagnostics, Branchburg, NJ)(DBS- DNA PCR) 
(figure 10).  
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Figure 10: Algorithm for HIV testing and determination of incidence cases. 
 
HIV testing (Study IV) 
Two concurrent commercial enzyme-linked immunosorbent assays (ELISA) kits, Murex HIV 
Ag/Ab (Abbott Murex, Dartford, UK) or GenScreen™ HIV 1/2 version 2 (Bio-Rad,  Hercules, 
California, USA) and Enzygnost anti-HIV-1/2 Plus (Dade Behring, Marburg, Germany) were 
used for initial HIV screening. For eligibility purposes, both ELISA results were required to be 
non-reactive. Discordant results on the ELISA assays were resolved using HIV-DNA PCR 
(Roche Amplicor HIV-1 DNA test, version 1.5, Roche Molecular Diagnostics, Branchburg, 
NJ). Reactive results were then confirmed by a HIV-RNA PCR assay (COBAS® Taqman®48 
analyzer, Roche Molecular Diagnostics, Mannheim, Germany). 
HBV testing (Study I and II) 
All serum samples were tested for HBsAg and Anti-HBc. Positive samples for Anti-HBc were 
tested for Anti-HBs and for HBeAg. HBeAg testing was performed using the commercial Elisa 
HBeAg/Ab Kit (Radim, Pomezia, Italy) and for other markers, Elisa kits from HUMAN GmbH, 
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Wiesbaden, Germany were used. All tests were performed according to the manufacturers´ 
recommendations. 
Syphilis testing (Study I) 
Syphilis diagnosis was performed using the SD Bioline Syphilis 3.0 Rapid Diagnostic Test 
(Standard Diagnostics, Suwon City, South Korea).  
 Pregnancy testing (Study I and IV) 
The pregnancy testing was done in all females prior to collection of blood samples using the 
QuickVue One-Step hCG Urine Test (Quidel Corporation, USA). 
HIV-1 viral load (Study I and IV) 
The HIV-1 viral load was measured using a COBAS Taqman48 analyzer (Roche Molecular 
Diagnostics, Mannheim, Germany). 
Immunophenotyping (Study I, III and IV) 
Lymphocyte subset immunophenotyping was performed using a FACSCalibur flow cytometer 
(Becton-Dickinson, Franklin Lakes, New Jersey, USA). Briefly, 20 μl of CD3 FITC 
/CD16+CD56 PE/CD45PerCP /CD19APC or CD3FITC/CD8PE/CD45perCP/CD4APC 
MultiTest reagents (Becton-Dickinson) were added into TruCOUNT tubes (Becton-Dickinson) 
and then mixed with 50μl of whole blood. The tubes were incubated in the dark, at room 
temperature for 15 minutes. Red blood cells were then lysed by adding 450 μl of fluorescence-
activated cell sorter lysing solution (Becton Dickinson) and incubating for 15 minutes, at room 
temperature. The samples were then analysed in the Flow cytometer using MultiSET software 
(Becton-Dickinson). A CD4 count for HIV infected individuals followed the procedure described 
above (Study I and IV). 
Complete blood count (CBC) (Study III and IV) 
A complete blood count and differential was done using the Sysmex KX-21N Hematology 
Analyzer (Sysmex Corporation; Kobe Japan) as recommended by the manufacturer. The EDTA 
blood samples were analyzed within 6 hours of specimen collection. The machine automatically 
dilutes a whole-blood sample, lyses, counts and gives a printout of the results. 
 
 32 
Biochemistry analysis (Study III and IV) 
Biochemistry analyses were performed using a Vitalab Selectra Junior (Vital Scientific) 
according to the manufacturer´s instructions.  Serum were separated within 4 hours of collection 
and analysed within 7 hours of the blood draw. Each sample was analysed for creatinine, aspartate 
aminotransferase (AST), alanine transaminase (ALT), bilirubin, albumin, glucose, uric acid, urea, 
amylase, HDL cholesterol, triglycerides and alkaline phosphatase (ALP). 
 
4.1.3. Statistical analysis 
The statistical methods used are described in detail in each paper. In papers I and II, statistical 
analyses were performed using Stata, version 12 and 14, respectively.  The participants were 
characterized according to target variables using descriptive statistical methods. The prevalence 
of HIV, syphilis and HBV (HBsAg) infection, and of other HBV seromarkers was defined as the 
percentage of positive results and a 95% confidence interval (CI) was calculated for each 
prevalence rate.  
The HIV incidence rate (IR) was calculated as the number of new HIV cases divided by the 
person-years (PY) of observation accumulated by the cohort. The age-specific changes of 
prevalence of the serologic markers HBsAg and Anti-HBc was used to estimate the incidence of 
HBV by using catalytic modelling.  
Associations between HIV and HBV seromarkers (HBsAg and Anti-HBc) and possible risk 
factors (socio-demographic, sexual and behavioural) were tested with the chi-square test. The 
magnitude of associations was assessed using odds ratios (OR) for HIV and prevalence ratios 
(PR) for HBV markers with respective 95% CI, and logistic regression models were used to 
control target variables. A two-sided P < 0.05 result was considered statistically significant. 
In paper III, data analysis was performed using R statistic software (version 3.0.0).  Median and 
95% reference ranges (2.5th- 97.5th percentiles) were established for all parameters analysed. 
The Mann-Whitney U test was used to determine differences by gender. For all analysis the 
significance was set at 0.05. For the parameters that did not meet the recommended minimum 
sample size of 120 individuals recommended by the Clinical and Laboratory Standards Institute 
(CLSI) (107), percentiles were obtained from a bootstrap procedure as described previously (108; 
109). 
 33 
4.1.4. Ethical considerations 
Approvals were granted by the National Health Bioethics Committee of Mozambique Ref. 
380/CNBS/08 and amendments: Ref. 422/CNBS/08, Ref. 148/CNBS/09, Ref. 84/CNBS/10, Ref. 
143/CNBS/11 and Ref 117/CNBS/12. Written informed consent was obtained from each 
participant prior to conducting any study procedures. 
 
4.2. Paper IV: Phase I HIV vaccine trial in Mozambique 
 
4.2.1. Study design and population 
The safety and immunogenicity of intradermal HIV-DNA priming at a dose of 600µg or 1200µg 
followed by intramuscular HIV-MVA boosts was evaluated in a phase I HIV vaccine trial 
conducted in Maputo, Mozambique – TaMoVac 01. The trial took place at the Polana Caniço 
Health Research and Training Centre in Maputo, from August 2011 to March 2013. Twenty-
four healthy volunteers, aged 18-26 years, were recruited at the Youth Clinic of the Maputo 
Central Hospital. The recruited volunteers participated in the cohort study reported in paper I. 
The participants were randomized into two groups either to receive the low or high dose of 
HIV-DNA vaccine using a needle-free device, the Zetajet™, followed by two doses of 
recombinant MVA expressing HIV genes using syringe. Within each group, subjects were 
randomized to receive the vaccine or placebo (normal saline) at a ratio of 5:1. The study team 
and participants were blinded to the randomization groups (Figure 11 and table 3). 
 
4.2.2. Vaccines 
The HIV-DNA vaccine candidate that was produced by Vecura (Huddinge, Stockholm) is 
composed of seven DNA plasmids containing different HIV genes: Pool 1 encoding Env 
subtypes A, B and C and Rev subtype B; and Pool 2 encoding Gag subtypes A and B and RTmut 
subtype B (110). The HIV-MVA vaccine candidate is a live recombinant non-replicating 
poxvirus vector that has been genetically engineered to express HIV-1 gp160 (Subtype E, 
isolate CM235) and Gag and Pol (integrase-deleted and reverse transcriptase non-functional, 
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Subtype A, isolate CM240) (111). The HIV-MVA vaccine was manufactured at WRAIR, 
Rockville, USA. 
 
 Figure 11: Vaccines, immunization time points and immunogenicity assays. 
 
 Table 3: Randomization, dose and study groups. 
 
 
 
 
 
 
Group Number of 
Volunteers 
DNA immunization 
Weeks 0, 4 and 12 
MVA boost 
Weeks 24 and 36 
IA 10 600 µg i.d. (2 x 0.1 ml) 
MVA, at 10
8
 pfu i.m. 
IB 2 Saline i.d. (2 x 0.1 ml) Saline, i.m. 
IIA 10 1200 µg i.d. (2 x 0.2 ml) 
MVA, at 10
8
 pfu i.m. 
IIB 2 Saline i.d. (2 x 0.2 ml) Saline, i.m. 
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4.2.3. Safety evaluations 
Safety assessment was performed clinically and by laboratory safety tests. Thirty minutes after 
vaccination, the participants were observed for vital signs and local and systemic reactogenicity. 
Subjects were asked to make a daily record of any reaction in the post-vaccination diary card for 
seven days after each immunization, and to contact the clinic if any moderate or severe reaction 
occurred. ECG was performed at screening and 2 weeks after each HIV-MVA immunization as 
per the US FDA requirements. Blood samples for routine laboratory tests were collected 2 weeks 
after each immunization. The laboratory safety tests included CBC, ALT, creatinine, random 
blood glucose, and total and direct bilirubin. Pregnancy test for females, urinalysis and HIV tests 
for all were performed at screening, prior to each vaccination and at the last visit. The participants 
were required to have normal urinalysis results prior to each vaccination. Participants with 
positive HIV and pregnancy test results after enrolment were considered ineligible for 
vaccination, but were followed until the end of the trial, or post-delivery for pregnant women, for 
safety assessments. 
All adverse events (AEs) that occurred during the trial were recorded. The DAIDS toxicity tables 
(version 1.0, December 2004, clarification August 2009) were used for grading the clinical and 
laboratory AEs.   
 
4.2.4. Immunogenicity evaluations 
Cell mediated immune (CMI) responses was assessed by the IFN-γ ELIspot assay, using fresh 
PBMCs collected at baseline, two weeks after third HIV-DNA immunization, and two weeks 
after the first and second HIV-MVA boost. HIV-1-specific peptide pools representing the DNA 
vaccine subtype A and B Gag, and MVA vaccine CRF01_AE Gag, Env and Pol were used. Serum 
samples were used in all antibody assays.  Binding antibodies assay was performed using samples 
collected at baseline, four weeks after the first and second HIV-MVA boost, and HIV proteins 
(recombinant HIV-1CN54 clade C gp140 (Centre for AIDS Reagents, NIBSC Potter Bar, UK) 
and native gp160 subtype B (HIV-1IIIB, Advanced Biotechnologies Inc., Columbia, MD) in in-
house ELISAs. NAb, Antibody‐dependent Cellular Cytotoxicity (ADCC) and epitope mapping 
assays were performed using samples from baseline and four weeks after the second HIV-MVA 
boost immunization. NAb were measured using TZM-bl assay with pseudoviruses SF162.LS 
(subtype B) and 93MW965.23 (subtype C) and using PBMC assay with infectious molecular 
clone (IMC) SF162.LS (subtype B) and CM244 (CRF01_AE). ADCC activity was measured 
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using assay employing Env.IMC.LucR virus-infected cells (CM235 CRF01_AE IMC) as targets. 
Figure 11 shows the vaccines, immunization time-point and immunogenicity endpoints. 
 
Peptide microarray 
HIV-1 Env-specific IgG was assessed using microarray slides from JPT Peptide Technologies 
GmbH (Berlin, Germany). Each array consisted of 8 full-length globally representative Env 
sequences, CN54gp140 and MVA-CMDR encoded Env immunogens, and additional peptide 
variants for hot spots of IgG recognition. The microarray slides were placed in incubation 
chambers.  Arrays were blocked with 990 µl of Superblock T20 PBS blocking buffer (Thermo 
Scientific) for 10 min at room temperature (RT) on a shaker. Then, 10 µl of each plasma sample 
was added to Superblock, diluting the sample 1:100. Arrays were then incubated for 2h at RT on 
a shaker. After incubation, arrays were washed five times with PBS containing 20% Tween, for 
3 min on a shaker for each wash. Arrays were then incubated for 1h at RT on a shaker with a 
secondary antibody, 1 mg/ml anti-IgG Cy5 antibody, diluted 1: 5000 with Superblock T20. 
Arrays were then washed 5 times with PBS and then 5 times with de-ionized water, for 3 min on 
a shaker for each wash. The arrays were let to dry at RT in the dark and scanned with a Genepix 
4000 Scanner (Axon Instruments, Union City, Calif.) at a wavelength of 650 nm and 532 nm 
lasers, at 500 PMT and 100 laser power. 
Microarray data analysis 
The raw images were analyzed using Genepix Pro 6.0 software (Molecular Devices) and Array 
List (GaL) file, provided by JPT creating a Genepix Results (GPR) file that contained information 
about the fluorescent intensity of each feature, with the name and position on the slide. R scripts 
software was then used to calculate the Mean fluorescent intensity (MFI) of the triplicates of each 
feature (peptide spot). The fluorescent intensities measured post-vaccination were corrected by 
subtracting the baseline value for that sample. The corrected fluorescent intensity was then 
compared to the threshold for positivity (2500 MFI), and all values above the threshold were 
considered positive. 
Results from the R analysis were transferred to an excel file and the frequency of responders were 
calculated for each positive peptide intensity in the vaccinees and in the study groups. To assess 
the magnitude of responses, the MFI for each positive peptide in the study groups was determined. 
Subsequently, analysis of significance was performed to identify antigen features (sequences) 
with statistically significant reactivity in each study group related to paired samples (pre- and 
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post-vaccination samples). These calculations were performed with R scripts software and P-
value < 0.05 was considered statistically significant. Sequences with statistically significant 
antibody reactivity were introduced in the HIV-1 sequence database to identify the amino acid 
start position aligned to the HXB2 HIV-1 strain. 
 
4.2.5. Study endpoints 
The study safety endpoints were any grade 3 or above, clinical or laboratory (only if clinical 
significant), adverse event that occurred after the first immunization until the last study visit. The 
primary immunogenicity endpoint of the trial was IFN-γ ELISpot responses to either Gag or Env 
peptide pools, two weeks after the first and second HIV-MVA vaccinations. The secondary 
immunogenicity endpoints were the magnitudes of the IFN-γ ELISpot responses to Gag or Env 
peptide pool stimulation, determined two weeks after the first and second HIV-MVA vaccination, 
and the antibody responses to HIV-1 subtype C gp140 and subtype B gp160, NAb, ADCC activity 
and IgG binding antibodies against HIV-1 Env regions were determined four weeks after the 
second HIV-MVA vaccination. 
 
4.2.6. Statistical analysis 
Clinical and safety laboratory data were double entered in a MySQL database and 
immunological data in Excel under study code. Data was exported and analyzed in SPSS 21.0. 
Descriptive statistics were used to summarize baseline characteristics. Categorical variables 
were expressed in percentages and continuous data as means with respective standard 
deviations (SD).  
Most immunological data was presented without statistical analysis, as this was a descriptive, 
hypothesis-generating study. The median magnitude of IFN-γ ELISpot responses and antibody 
titers were compared using the Mann-Whitney U-test. Fischer’s Exact test was used for 
comparison of frequencies of responses between groups. A p-value of < 0.05 was considered 
statistically significant. 
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4.2.7. Ethical considerations 
The trial was approved by the National Health Bioethics Committee of Mozambique (ref. 
76/CNBS/11 and 142/CNBS/11) and by the Regional Ethics Committee, Stockholm, Sweden 
(2011/1684-31-4). Written informed consent was obtained from each study participant. The 
participants were required to have passed a test of understanding before screening procedures 
were initiated. 
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5. MAIN FINDINGS  
 
5.1. Paper I 
 
5.1.1. Suitability of the youth cohort in Maputo for phase I/II HIV vaccine trials  
A total of 1380 youths, 320 (23.2%) males and 1060 (76.8%) females, were enrolled in the 
study. The age of the participants ranged from 18 to 24 years (mean was 20.9, SD ± 1.71), with 
males being older than females (21.7 vs. 20.7, p ˂ 0.001). The overall prevalence of HIV-1 at 
baseline was 5.1% (95%CI: 3.97–6.31). Females had a significantly higher prevalence of HIV-
1 (5.8%) as compared to males (3.1%), p =0.018. The overall incidence of HIV-1 was 
1.14/100PY (95% CI: 0.67–1.92). In our study, all incident cases occurred in females. The HIV 
incidence rate among women was 1.49/100 Women Years (WY) (95%CI: 0.88–2.51). 
Retention rates were stable throughout the study, being 85.1% at the last visit. Figure 12 shows 
the HIV infections among participants and retention during the study.  
 
  Figure 12:  HIV infections among participants and retention during the study. 
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5.1.2. HBV and syphilis prevalence, and co-infections with HIV in young adults in 
Maputo, Mozambique 
Overall HBsAg prevalence in this study was 12.2% (95%CI: 10.5%–14.0%) with males having 
a higher prevalence of HBV infection than females (15.9% vs. 11.1%, p = 0.02). The overall 
syphilis prevalence was 0.36% (95%CI: 0.15%–0.84%). Here, 11.3% of HIV-infected 
participants were also infected by HBV and all participants with a reactive syphilis test had 
other sexually transmitted viral infections (HIV and/or HBV). 
 
5.2. Paper II 
 
5.2.1. Prevalence of HBV seromarkers in young adults in Maputo City, Mozambique 
In paper II a more detailed analysis of markers of HBV infection was performed. A total of 
1377 volunteers were screened for HBV seromarkers, among them 1057 (76.8%) were females 
and 320 (23.2%) were males. The prevalence of HBV exposure (Anti-HBc), HBV infection 
(HBsAg), chronic carriers (HBsAg and Anti-HBc), and acute infection (HBsAg only) were 
42.8%, 12.1%, 8.5% and 3.6%, respectively. The prevalence of HBsAg and of Anti-HBs was 
significantly higher among men than in women, 15.9% vs. 11.0%, p=0.016 and 48.8% vs. 
41.0%, p=0.012, respectively. There was no statistical difference between genders with regard 
to the prevalence of chronic HBV infection.  
All volunteers with anti-HBc positive results were tested for anti-HBs and HBeAg. The 
prevalence of these markers was 45.5% and 6.8%, respectively. The prevalence of anti-HBs 
was higher in females than in males (46.7% vs. 42.5%) and the frequency of HBeAg was higher 
in males than in females (7.8% vs. 6.5%), although, these differences did not reach statistical 
significance (table 4). Figure 13 shows the algorithm for HBV seromarkers detection. 
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Figure 13: Algorithm for HBV seromarkers detection. 
 
Table 4: Prevalence of HBV seromarkers among young adults in Maputo City, Mozambique. 
HBV seromarkers 
Female Male Total 
p-value 
Tested 
Prevalence  
(95% CI) 
Tested 
Prevalence 
 (95% CI) 
Tested 
Prevalence  
(95% CI)  
HBsAg 1057 11.0 (9.2 - 13.0) 320 15.9 (12.1 - 20.4) 1377 12.1 (10.4 - 14.0) 0.016 
Only HBsAg 1057 3.2 (2.2 - 4.5) 320 5.0 (2.9 - 8.0) 1377 3.6 (2.7 - 4.8) 0.137 
Anti-HBc 1055 41.0 (38.1 - 44.1) 320 48.8 (43.2 - 54.4) 1375 42.8 (40.2 - 45.5) 0.012 
HBsAg and Anti-HBc 1055 7.8 (6.2 - 9.6) 320 10.9 (7.7 - 14.9) 1375 8.5 (7.1 - 10.1) 0.075 
HBeAg 431 6.5 (4.4 - 9.3) 154 7.8 (4.1 - 13.2) 585 6.8 (4.9 - 9.2) 0.584 
Anti-HBs 431 46.7 (41.8 - 51.5) 153 42.5 (34.5 - 50.7) 584 45.5 (41.5 - 49.7) 0.385 
HBsAg(+), AntiHBc(+) 
and HBeAg(+) 
431 5.3 (3.4 - 7.9) 154 5.8 (2.7 - 10.8) 585 5.5 (3.4 - 7.6) 0.812 
HBsAg(-), Anti-HBc(+) 
and Anti-HBs (+) 
431 36.9 (32.3 - 41.6) 153 32.0 (24.7 - 40.0) 584 35.6 (31.7 - 39.7) 0.290 
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5.2.2. Incidence of HBV in young adults in Maputo City, Mozambique 
The incidence of HBV was estimated using the age changes of prevalence of the serologic 
markers HBsAg and Anti-HBc using catalytic modelling. The overall HBV incidence rate was 
180 (95% CI: 130 – 230) per 100,000 PY when we used the prevalence of HBsAg in the model. 
We did not find statistically significant differences between genders in the incidence rates 
estimated using the prevalence of HBsAg, p = 0.168. The HBV incidence rate was estimated to 
be 2690 (95% CI: 2470-2920) per 100,000 PY when we used the prevalence of Anti-HBc in 
the model.  In this case, males had a significantly higher HBV incidence rate compared to 
females, 3130 (95% CI: 2670 - 3670) per 100,000 PY vs. 2560 (95% CI: 2320 - 2810) per 
100,000 PY, respectively, p = 0.033. 
 
5.3. Paper III 
 
5.3.1. Clinical laboratory reference values for Mozambican young adults and comparison 
with those from the same age group in other African countries and values from the 
US 
A total of 257 youths (102 males and 155 non-pregnant females), HIV, HBV and syphilis 
negative were enrolled in the study. Due to low attendance of males at the Youth Clinic, the 
target of ˃ 120 males was not reached. The full range of lymphocyte subsets, hematology and 
chemistry analytes was not run in all subjects, primarily due to insufficient access to reagents 
required to test some parameters. However, a robust bootstrap analysis was used to eliminate 
bias due to the small sample size. 
Analyses of immunological parameters revealed statistically significant differences between 
genders in some parameters. Most relevant, females had significantly higher values of absolute 
(824 vs. 713 cells/µl, p<0.0001) and percentage (40.4 vs. 35.5 cells/µl, p<0.0001) CD4+ cells 
count, and CD4:CD8 ratio (1.7 vs. 1.5, p=0.0001) than males. The immunology reference 
ranges derived from this study were comparable to those reported for the USA and western 
Kenya. The hematological values derived from this study differed from the USA values. In 
most cases, the study-derived values were lower than those derived from the USA population. 
More than 50% of the participants had Hb values that were outside the lower limits of the USA 
reference range, among them 69.3% were female. Our values were similar to reports of 
populations in western Kenya and Uganda. The chemistry ranges derived here were lower 
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compared to those from western Kenya in the same age group. The Maputo values were 
comparable to USA values, with a few exceptions. The upper limits of the study reference 
ranges for ALT, AST, bilirubin and cholesterol were somewhat higher than those from the 
USA. Table 5 shows the comparison of laboratory reference ranges (of the most important 
parameters used in clinical studies to assess the safety of the study products) from Maputo, 
western Kenya, Uganda and USA. 
 
Table 5: Comparison of laboratory reference ranges derived from young adults in Maputo, 
Mozambique compared with those from western Kenya and the United States of America. 
Parameter Maputo-Moz. 
(18-24 years old) 
Western Kenya  
(18-34 years old) 
 
Uganda  
(19-24 years old) 
USA  
Hemoglobin (g/dL)     
Male 12.3 – 16.0 11.4 – 16.9 11.5–17.1 13.5-17.5 
Female 7.3 –  13.2 8.0 – 14.2 9.9–13.7 12.0-16.0 
Platelets  (10˄6 cells/μl) 125.2 – 488.0 a 103 - 390 NA 150 - 350 
WBC (10˄6 cells/μl) 3.0 – 8.7 a 3.3 – 9.3 3.7–9.7 4.5 – 11.0 
Neutrophils  (10˄3 cells/μl) 1.2 – 6.1 a  0.9 – 5.2 1.0–3.5 1.8 – 7.7 
Lymphocytes (10˄3 cells/μl) 1.1 – 3.1 a  1.1 – 3.5 1.3–4.1 1.0 – 4.8 
T CD4 (Cells/ μl) 381 – 1340 444 –  1488 NA 404 - 1612 
ALT (U/L) 5.0 – 48.2 7.2 – 61.3 NA 0 - 35 
AST (U/L) 13.7 – 42.8 13.8 – 50.4 NA 0 - 35 
T-Bil (μmol/L) 4.4 –  27.9 5.1 – 40.7 NA 5.1 – 17.0 
Creatinine(μmol/L) 47.1 – 103.2 50 – 113 NA 0 - 133 
Glucose (mmol/L) 3.1 – 5.5 2.1 – 6.6 NA 4.2 – 6.4 
a
Values corresponding to individuals aged 13–34 years. 
NA – Not available. 
 
5.3.2. Implications of the study derived reference values in clinical trials  
A comparison between the study derived values and those from the USA showed higher 
variations in most values, especially in hematological parameters. Overall, 159 (62%) of the 
study participants would have been excluded in potential clinical studies due to abnormal 
laboratory values, if USA reference ranges were used in this group as inclusion and/or exclusion 
criteria to assess participant eligibility. However, if the local reference ranges were used, only 
40 (16%) of the participants would have been excluded. The hematological and clinical 
chemistry parameters would have been the most important cause of participant exclusion. The 
DAIDS toxicity tables for grading adverse events, which have been used in many clinical trials, 
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predicted 297 adverse events in the laboratory values obtained from the blood samples of the 
study participants. In respect to the hematologic parameters, Hb and neutrophil counts 
accounted for the majority of the AEs, 32 and 16 AEs, respectively. Among the clinical 
chemistry parameters, ALT and AST would have resulted in 27 and 197 AEs, respectively 
(table 6).  
 
Table 6: Frequency of predicted adverse events in the youth cohort based on a comparison with 
DAIDS values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Ineligible 
per US 
Comparison 
Interval 
 
DAIDS toxicity grading 
 
Parameter 
 
 
  
Grade 1 
 
Grade 2 
 
Grade 3 
 
Grade 4 
 
 
N 
 
n (%) 
 
n (%) 
 
n (%) 
 
n (%) 
 
n (%) 
 
Hemoglobin (g/dL) 
 
 
    
 
Male 
 
100 
 
14 (14) 
 
1(0.9) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
Female 
 
150 
 
104 (69.3) 
 
20 (13.2) 
 
7 (4.6) 
 
4 (2.6) 
 
0 (0) 
 
Platelets  (10˄6 cells/μl) 
 
253 
 
47 (18.6) 
 
3 (1.2) 
 
4 (1.6) 
 
0 (0) 
 
0 (0) 
 
WBC (10˄6 cells/μl) 
 
252 
 
64 (25.4) 
 
1 (0.4) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
Neutrophils  (10˄3 cells/μl) 
 
254 
 
24 (9.4) 
 
14 (5.5) 
 
2 (0.8) 
 
0 (0) 
 
0 (0) 
 
Lymphocytes (10˄3 cells/μl) 
 
247 
 
3 (1.2) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
T CD4 (Cells/ μl) 
 
226 
 
4 (1.8) 
 
6 (2.7) 
 
1 (0.4) 
 
0 (0) 
 
0 (0) 
 
ALT (U/L) 
 
253 
 
15 (5.9) 
 
22 (8.7) 
 
5 (1.9) 
 
0 (0) 
 
0 (0) 
 
AST (U/L) 
 
253 
 
14 (5.5) 
 
145 (57.3) 
 
52 (20.6) 
 
0 (0) 
 
0 (0) 
 
T-Bil (μmol/L) 
 
253 
 
38 (15.0) 
 
5 (1.9) 
 
1 (0.4) 
 
0 (0) 
 
0 (0) 
 
Creatinine(μmol/L) 
 
253 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
Glucose (mmol/L) 
 
251 
 
104 (41.1) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
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5.4. Optimizing the dose of the HIV-DNA prime vaccine - Paper IV 
 
5.4.1. Comparison of vaccines safety among participants who received low doses (600µg) 
and high doses (1200µg) of the HIV-DNA vaccine 
Of the 24 enrolled subjects, 23 (96%) and 21 (88%) reported at least one local and one systemic 
solicited adverse event (AE) during the trial, respectively. Most (94.8%) of these events were 
mild.  The common local solicited AE in vaccines was pain, which occurred in 18 of 20 (90.0%) 
participants. The most common systemic solicited AE was a headache, occurring in 17 of 20 
(85.0%) participants. There were 166 unsolicited clinical AEs, 165 non-serious and one serious 
AE, reported by vaccine recipients during the course of the trial. The serious AE, HIV infection, 
was reported in a male subject in the high HIV-DNA dose group. The HIV test result at the 
time of the first HIV-MVA boost was indeterminate and confirmation of infection was done 15 
days after the vaccination. 
There were 88 laboratory AEs reported in the vaccine recipients. All laboratory AEs were 
considered “not related” or “possibly not related” to the investigational products. No ECG 
abnormalities were seen after the two HIV-MVA boosts.  
Overall, the distribution of AEs was balanced between the vaccination groups. 
 
5.4.2. Comparison of vaccines immunogenicity among participants who received low doses 
(600µg) and high doses (1200µg) of the HIV-DNA vaccine 
HIV-specific cell-mediated immune response 
The overall IFN- ELIspot responses rate to Gag and/or Env was 14/15 (93%) and 8/10 (80%) 
two weeks after the first and after the second HIV-MVA boost, respectively.  There was no 
significant difference in response rates to Gag and Env between the low and high DNA dose 
groups after the HIV-MVA immunizations. 
After the HIV-MVA boosts, no difference in median magnitudes of the responses to Gag 
CMDR was seen between the low and high HIV-DNA immunization groups. IFN-γ responses 
to Env was significantly higher after the first MVA-HIV boost in the high dose group compared 
to the low dose group, when comparing all vaccinees (157.5 vs. 420 SFC/million PBMC, 
p=0.014), and a trend towards a difference was observed when only responders were compared 
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(150 vs. 420 SFC/million PBMC, p=0.0513). After the second HIV-MVA vaccination no 
differences in IFN- ELIspot responses between study groups were observed. In pair wise 
analysis of the IFN-γ ELIspot data, Gag CMDR responses were significantly higher after the 
first HIV-MVA vaccination, rather than after the second HIV-MVA vaccination (median, 360 
vs. 142 SFC/million PBMC to Gag CMDR, p=0.0391). The IFN-γ responses to Env did not 
differ significantly between the two time points (median, 148 vs. 118 SFC/million PBMC),        
p = 0.6523. 
HIV-specific Humoral Immune Responses   
At baseline, binding antibodies were not detected among vaccinees. Four weeks after the second 
HIV-MVA boost, the overall median antibody titer to subtype C gp140 was 800 (range 400-
3200) and 400 to subtype B gp160 (range 200-800). The median antibody to subtype C gp140 
and to subtype B gp160 was higher in the high dose group than in the low dose group, but the 
differences did not reach statistical significance, median 2000 vs. 800, p = 0.1993 and median 
400 vs. 300, p = 0.1602, respectively. 
There was no demonstrable NAb activity in the TZM-bl and PBMC neutralization assays in 
any of the vaccinees. ADCC-mediating antibodies against to CRF01_AE CM235 were only 
detected in two (13%) of 16 vaccinees, one in each of the HIV-DNA immunization groups. 
 
5.4.3. Antibody epitope mapping of HIV-vaccine specific responses (preliminary results) 
 
Significance analysis of microarrays 
Table 1 shows the list of antigen features (sequences) that had statistically significant antibody 
reactivity in the vaccinees four weeks after the last HIV-MVA vaccination. Across all 
vaccinees, Env-specific IgG responses were confined to few antigenic sites in V2, V3 and gp41 
immunodominant regions of gp120 protein. A higher number of antigenic sites were recognized 
by high dose DNA recipients than low dose DNA recipients.  
Frequency and Magnitude of IgG binding in peptide microarray 
Figure 14 shows the frequency of IgG antibody responses among the vaccinees. Among the 
vaccinees, 8/16 (50%) had antibodies against at least one antigenic site in the V2 loop.  The 
frequency of responders with responses against the V2 loop was significantly higher in the high 
dose group than in the low dose group, 6/8 (75%) vs. 2/8 (25%), respectively, p = 0.0486. Visual 
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inspection of the data identified peptide 176 (HXB2 numbering sequence 164→178) as most 
frequently recognized in the V2 region among the vaccinees. Of the 16 vaccinees, 9 (56.3%) 
had antibody responses to the V3 loop and the sequence most frequently recognized was 
TSIPIGPGQAFYRTG (peptide 326 on array, HXB2 numbering sequence Env 307→321). The 
IgG response rate to the V3 loop was higher in the high dose group than in the low dose group 
but without a statistically significant difference (75% vs. 50%, p = 0.1492) (Fig. 2). Antibodies 
to the gp41immunodominant region were detected in 9/16 (56.3%) vaccinees and the sequence 
VLAVERYLKDQKFLG (peptide 612 on array, HXB2 numbering sequence Env 580→594) 
was recognized by all responders. There was no statistically significant difference in the 
proportion of responders to the gp41immunodominant region between the vaccination groups. 
Four vaccinees, two in each vaccination group, had antibody responses against the amino acid 
sequence PDRLGRIEEEGGEQD (peptide 759 on array, HXB2 numbering sequence Env 
727→741). Among peptides that had statistically significant antibody reactivity across the 
vaccinees (175, 325 and 612, peptide positions on array, table 1), we did not find significant 
differences between groups.  
The magnitude of the Env-specific antibody responses was measured by MFI. There was no 
statistically significant difference between the vaccination groups in the magnitude of responses 
to any of the Env regions (figure 15). 
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Table 1. Peptides with statistical significance reactivity in the vaccination groups. 
Regions 
Position on 
array 
Antigen feature 
(HXB2) 
Sequences Low-dose 
group 
High-dose 
group 
 
175  Env 163→177 
TEIKDKKQKVHALFY  X 
 
TELRDKKQRVHALFY  X 
 
TEIRDKKQRVHALFY  X 
 
TELRDKKKKVHSLFY  X 
V2 TEIKDKKKKVHALFY  X 
 
TELRDKKKKVHALFY  X 
 
TELRDKKRKVHALFY  X 
 
TELRDKKQKVHSLFY  X 
 
TELKDKKHKVHALFY  X 
 176 Env 164→178 ELRDKKQKVHALFYK  X 
V3 322 Env 301→317 NNTRTSIPIGPGQAF  X 
 325 Env 304→320 RKSIPIGPGRAFYTT X X 
   
RKSIPIGPGRAFYAT  X 
 326 Env 307→321 TSIPIGPGQAFYRTG  X 
gp 41 
Immunodominant  
608 
Env 576→590 LQARVLAIERYLKDQ  X 
 612 Env 580→594 VLAVERYLKDQKFLG  X 
  624 Env 592→606 FLGLWGCSGKIICPT  X 
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Figure 14. Frequency of antibody responses to HIV Env peptides in the vaccination groups. 
A and B show the frequency of antibody responses in low-dose group and high-dose group, 
respectively. 
 
Figure 15. Shows the magnitude of antibody responses to HIV Env peptides in (A) low-dose 
group and (B) high-dose group. 
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6. DISCUSSION 
 
6.1. Paper I  
 
6.1.1. Suitability of the youth cohort in Maputo for phase I/II HIV vaccine trials  
The overall prevalence of HIV (5.1%) in our study is similar to the prevalence of 4% reported 
in a study performed from November 2002 – April 2003 at the same youth clinic (112), but is 
lower than the national estimated prevalence of 10.9% for this age group in 2009. The free 
services offered by the youth clinic (HIV counselling and testing, STI diagnosis and treatment, 
condom provision and sexual behaviour education) could have contributed to the lower HIV-1 
prevalence reported in both studies. Females had a significantly higher HIV prevalence (5.8%) 
as compared to males (3.1%), p = 0.018. Similar findings were previously reported in the 
country (15)  and in other African countries (113; 114; 115), supporting the suggestion that 
women are more affected by the HIV-1 epidemic than men.   The overall incidence of HIV-1 
in our study was 1.14/100PY, which is lower compared to that found in previous studies 
conducted in the Mozambique, which indicated an HIV incidence in different groups that vary 
from 3.2 to 6.5 per 100 women years (WY) (116; 117; 118). In our study, all incident cases 
occurred in females, the HIV incidence rate among women was 1.49/100 WY (95% CI: 0.88–
2.51). These findings further stress the need of additional intervention to protect young women 
from acquiring HIV infection. Retention rates in our study were similar to those reported by 
others (119) or even higher (120). 
The high retention rates, relatively low prevalence and incidence of HIV in this cohort 
suggested that this group was suitable for a phase I/II HIV vaccine trials in our setting. 
Therefore, we recruited participants from this cohort to participate in phase I and II HIV vaccine 
trials in Mozambique, the TaMoVac I trial and TaMoVac II trial (not presented here), 
respectively.  
 
6.1.2. HBV and syphilis prevalence, co-infections with HIV in young adults in Maputo 
City, Mozambique 
The overall HBsAg prevalence in this study was 12.2%, this is higher than the previously 
reported prevalence in the country, 6.0% to 10.6% in blood donors (89; 90; 91) and 8% in 
women from a rural area of southern Mozambique (92). The majority of youths in Mozambique 
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never received Hepatitis B vaccinations. Hepatitis B vaccination was introduced in the 
Mozambican national program of immunization in 2001. Our study demonstrates that youths 
are severely affected by HBV infection, and therefore, vaccination and health education 
campaigns targeting adolescents and young adults should be considered. In this study, 11.3% 
of HIV-infected participants were also infected with HBV. Similar findings have been reported 
in other studies from Africa (121; 122). Since co-infections with these viruses are common, 
HIV-infected patients should benefit from HBV screening and vaccination.  
The overall syphilis prevalence in our study was 0.36%, which was lower compared to that 
found in previous studies; 2.3% in the same population in volunteers recruited from 1 
November 2002 to 31 April 2003 (112), and 2.2 % the national value in pregnant women in 
2011 (123). Data from WHO indicates a trend of decline in rates of syphilis in Mozambique, 
from 7.9 % in 2008, 6.9% in 2009 to 5.7% in 2010, but the rate of infection is still high (72). In 
the present study, all participants with a reactive syphilis test had other sexually transmitted 
viral infections (HIV and/or HBV), suggesting that the route of transmission was likely to be 
the same and that infection with one STI increases the risk of acquiring other venereal infections 
(124). Therefore, further effort should be made to control syphilis and other STIs, which will 
also contribute to the prevention of HIV infections. In 2015, WHO launched the programme 
for validation of elimination of mother-to-child-transmission of HIV and syphilis. The success 
of this program will depend on the prevalence of disease in the country, health service coverage, 
and whether key populations with high transmission risk can access health services (125). 
 
6.2. Paper II 
 
6.2.1. Potential risk of HBV transmission from youths to their children or other 
unvaccinated persons 
We found a high prevalence of HBV seromarkers (12.1% for HBsAg and 42.8% for Anti-HBc) 
and HBV incidence (180 per 100 000 PY using HBsAg and 2690 per 100 000 PY using Anti-
HBc) in unvaccinated young adults in Maputo, Mozambique. Other studies conducted in 
Mozambique have also reported a high prevalence of markers of HBV infection, 6.0% to 10.6% 
for HBsAg (90; 92; 91; 89) and 63% to 64.5% for Anti-HBc (90; 92), confirming that HBV 
infections are endemic in the country. However, the prevalence of the HBsAg marker was much 
higher in our study than in previous studies, showing that the youth population are severely 
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affected by HBV infections. With regards to HBV incidence, previous studies conducted in 
Nigeria (126) and in Taiwan (127) have also reported a high incidence of this virus among 
youths.  
Among the study participants, 8.5% were chronically infected with HBV. Besides the health 
problems that these youths may develop as a consequence of HBV infection, they constitute 
reservoirs of asymptomatic human carriers, who are potentially infectious. These youths may 
transmit HBV infections to their children or other unvaccinated persons. The high prevalence 
and incidence of HBV among youths stress the need for additional intervention to control HBV 
infection, especially among sexually active individuals. Vaccination for adolescents and youths 
who were not vaccinated during childhood is one example. 
The prevalence of HBeAg in chronically infected females in our study was relatively low 
(6.5%), similar to what has been reported in other African countries (128; 129; 130). Despite 
the relatively low prevalence of HBeAg found in our study, the high prevalence (11.0%) and 
incidence (160 per 100 000 PY using HBsAg and 2560 per 100 000 PY using anti-HBc) of 
HBV infections among women of child bearing age, suggest that HBV vertical transmission 
may play important role in Mozambique, especially because neonatal immunization is not 
practiced in the country.  
 
6.3. Paper III 
 
6.3.1. Study derived reference values and comparison with those from other countries  
In the present study, females had significantly higher values of absolute and percentage CD4+ 
cells count, and CD4:CD8 ratio than males. Our findings are similar with those reported for 
adults in Kericho, Kenya (131). Other studies have also reported higher CD4+ T cell counts 
among females than among males (132; 133; 134; 135; 136). The study reference ranges were 
generally comparable to those from the Western Kenya and North American populations. 
Generally, the lower and upper limits of the USA reference ranges for all T cells were higher 
than those derived from this study. The hematological values derived from this study, in most 
cases, were lower than those derived from the USA population. This is consistent with studies 
conducted in western Kenya and Uganda involving similar age groups (132; 67). For many 
parameters, the lower limits of the ranges generated in the present study were lower than those 
derived from those African countries. About 50% of the participants had Hb values that were 
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outside the lower limits of the US reference range. Several factors have been suggested to 
account for low Hb values, including poor nutritional status, genetic red blood cell disorders or 
parasitic infections.  A study conducted in Mozambique showed that parasitic infections are 
common in country (137). The reference ranges for chemistry parameters derived from this 
study were lower compared to those from western Kenya in the same age group. The Maputo 
values were comparable to US values, with a few exceptions. The upper limits of the study 
reference ranges for ALT, AST, bilirubin and cholesterol were somewhat higher than those 
from the US, which is consistent with results from Uganda (65). The reasons for the variation 
of the laboratory reference values between populations include ethnic origin, genetics, gender, 
altitude and environmental factors (132; 138; 139). 
 
6.3.2.  Study derived reference values and implications for clinical trials 
Notably, a large proportion of the study participants (62%) would have been excluded in 
potential clinical studies due to abnormal laboratory values, if USA ranges were used as 
inclusion and/or exclusion criteria to assess participant eligibility. The hematological and 
clinical chemistry parameters would have been the main cause for participant exclusion. 
However, if the local reference values were used, only 40 (16%) of participants would have 
been excluded. It has been reported that the use of appropriate reference values contributed to 
reducing the workload and the study cost, by shortening the time period of trial enrolment (65). 
The DAIDS toxicity tables for grading adverse events (AEs), which have been used in many 
clinical trials, predicted 297 adverse events in the laboratory values obtained from the blood 
samples of the Maputo youths. These results are consistent with those reported in Uganda (65) 
and western Kenya (67), which also predicted a high number of AEs using the DAIDs tables. 
This suggests that the toxicity tables used in the intervention studies for safety evaluations may 
not be appropriate for the young adults included in the present study, because it might lead to 
over reporting of adverse events. 
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6.4. Optimizing the dose of the HIV-DNA prime vaccine - Paper IV 
A previous trial conducted in Tanzania (HIVIS03), which used the same vaccination strategy, 
showed that priming intradermal with 1000μg of HIV-DNA followed by an intramuscular HIV-
MVA boost induces broad and strong immune responses. The dose of 1000 μg of the HIV-
DNA vaccine was administrated using the Bioject® needle-free device in 5 injections of 0.1ml 
and separating Env and Gag plasmid pools (55). Another trial, the TaMoVac 01 Tanzanian 
study, evaluated the possibility of simplifying the regime used in HIVIS03 to 2 injections, using 
separated and combined plasmids. However, the maximum dose that could be delivered 
intradermally with the Bioject needle free device in 2 injections was 600 μg, since this device 
can only contain 0.1ml while the highest concentration of HIV-DNA available was 3 mg/ml. 
Thus a strict comparison between 2 and 5 injections could not be made. Nevertheless, the results 
of that trial showed that the simplified regimen (2 intradermal injections of a total of 600 μg of 
HIV-DNA), either using separated and combined plasmids, have similar priming effect as the 
standard regimen (5 intradermal injections of a total of 1000 μg HIV-DNA) (140). In the present 
trial, we compared the safety, tolerability and immunogenicity of priming with 2 intradermal 
injections of a total dose of 600 µg, with 2 intradermal injections of a total dose of 1200 µg 
using the needle-free Zetajet injection device that allows up to 0.2 ml intradermal injections, 
followed by HIV-MVA vaccinations.  This was the first study to assess HIV-DNA delivery 
using the Zetajet, in a volume of 0.2 ml intradermally. Overall, the vaccines were safe and well 
tolerated. A good safety profile of the use of this prime-boost vaccination strategy has been 
reported in previous trials (54; 55; 140). 
This vaccination strategy, HIV-DNA prime and HIV-MVA boost, was highly immunogenic in 
Mozambican vaccinees, with the high dose inducing stronger cellular immune responses than 
the low dose. After the first HIV-MVA boost, IFN-γ ELIspot responses to Env were 
significantly higher in vaccinees that received the higher DNA dose compared to those that 
received the lower dose (median 157.5 vs. 420 SFC/million PBMC, p=0.014), and a trend 
towards a difference was observed when only responders were compared (median 150 vs. 420 
SFC/million PBMC, p = 0.0513). In this trial, ELIspot responses to Gag and Env were higher 
after the first than after the second HIV-MVA boost as had been previously reported for this 
vaccine candidate (54; 140; 55) and by others using HIV-DNA subtype C and HIV-MVA (141). 
The lack of responses to the second HIV-MVA may be attributed to pre-existent immunity 
against the vector proteins as previously reported (142).   
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In the present study, binding antibodies were elicited in all vaccinees four weeks after the last 
HIV-MVA boost, similar to what we have previously reported (140; 55; 143; 57). Another trial 
that used a similar vaccination strategy reported a relatively lower frequency (75%) of binding 
antibodies (141). The HIV-MVA vaccine used in our study has been evaluated in a HIV-MVA-
alone strategy in the USA and Thailand. After immunization with three doses of 108 pfu HIV-
MVA, binding antibodies were elicited in 90-100% of participants (144).   
Vaccine-induced IgG binding antibodies against at least one antigenic site in the V2 loop were 
detected in 8/16 (50%) of the vaccinees. The frequency of anti-V2 responders was significantly 
higher in the high-dose group than in the low-dose group, 6/8 (75%) vs. 2/8 (25%), respectively, 
P=0.0486. The high dose of HIV-DNA induced the highest average number of antigenic sites 
recognized. These results give further evidence that priming with a high dose of HIV DNA 
might be beneficial for priming humoral immune responses. Pre-clinical studies have suggested 
that Env-specific antibodies are essential for blocking acquisition of infection (43). In addition, 
in the RV144 clinical trial, which demonstrated an efficacy of 31.2%, the presence of anti 
V1/V2 binding IgG antibodies were associated with protection (61).  
Overall, the results of this study suggest that priming with a high dose of HIV DNA (1200 µg) 
is safe and shows immunological advantage over the lower HIV-DNA dose (600 µg).  
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7. RECOMENDATIONS AND FUTURE PLANS 
 
We established a youth cohort and characterized the potential of this group to participate in phase 
I /II HIV vaccine clinical trials. We determined the prevalence of HIV, HBV and syphilis, as well 
as the incidence of HIV and HBV, and risk factors related to the spread of these STIs in the group. 
The results of this study indicated that this group is potentially a suitable population for phase I/II 
HIV vaccine trials in Mozambique. However, additional intervention should be made to further 
reduce the risk of acquiring HIV infection in this group. The participants included in these studies 
were not representative of the general Mozambican population. Therefore, community-based 
studies should be encouraged to better estimate the prevalence and incidence of HIV, HBV and 
syphilis within the overall population in Mozambique. 
Based on the high prevalence and incidence of HBV among young adults found in this study, we 
recommend the implementation of a HBV immunization program targeting this group and 
adolescents who were not vaccinated during their childhood. Additionally, we also showed that 
HBV/HIV co-infections are common among youths. Therefore, we recommend that HBV 
vaccination should be considered for HIV mono-infected patients to prevent HBV infections. 
Since the present study documented a high prevalence of HBV among women of childbearing 
age, we suggest that routine HBsAg screening be introduced for all pregnant women during the 
antenatal period and the first HBV vaccine dose be given within 24 hours of birth, for at least new 
born babies of mothers found to be HBsAg positive, to prevent perinatal transmission.  
Young adults, especially women, are severely affected by HIV infection in Mozambique. In the 
present study it has been shown, that once again, education plays an important role in HIV 
prevention. Therefore, we strongly recommend incorporating sexual education topics into the 
national education system that aim to reduce the risk of HIV infection and other STIs in 
adolescents and young adults.  
Clinical laboratory reference values derived from populations living in Europe and North 
America have been used in Mozambique for patient management, due to the absence of locally 
derived values. The results of this study provided the first indication that reference values derived 
from a Mozambican population differ from those derived from the populations mentioned above. 
Therefore, local reference values should be established for patient management and for clinical 
studies in Mozambique.   
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TaMoVac 01 was the first HIV vaccine clinical trial conducted in Mozambique. Through this 
study we increased capacity in the laboratories and in the clinic site of INS to conduct vaccine 
trials. As a result of this, we successfully conducted a multicentre trial, called TaMoVac II, which 
also included participants from the youth cohort. Currently, the site is conducting a HIV incidence 
study in high-risk populations, in preparation for phase IIb and III vaccine trials. 
We demonstrated that the delivery of HIV-DNA vaccine i.d. at concentration of 3 mg/mL, in a 
volume of 0.2 ml using the ZetajetTM intradermally was safe and highly tolerable in healthy 
Mozambican volunteers. Therefore, this study supports the use of the Zetajet™ for i.d. delivery 
of HIV-DNA. We have also shown the superiority of priming with the higher dose (1200 µg) of 
HIV-DNA to generate cell-mediated immune responses. We recommend a further large-scale 
study to confirm the results of the TaMoVac 01 Maputo.  
The findings presented here will guide future development of the HIV-DNA/HIV-MVA vaccine 
concept.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
8. ACKNOWLEDGEMENTS 
 
Firstly, I would like to especially thank all study participants, without them none of these studies 
would have been possible.  
I would also like to thank the Swedish International Development Agency (SIDA) for financially 
supporting the HIV incidence study and my training. Special thanks to European & Developing 
Countries Clinical Trials Partnership (EDCTP) for also supporting my training and the vaccine 
trial. 
I would like to thank my main supervisor, Ass. Professor Charlotta Nilsson, for all her support, 
expert guidance and supervision. Without her drive and never ending patience this thesis would 
not have been written. 
Thank you to my co-supervisor, Professor Sören Andersson for his assistance and support at all 
stages of my training. His input to this thesis is invaluable. 
Special thanks to Professor Ilesh V. Jani, my co-supervisor for introducing me into your research 
group and creating the opportunity for this PhD training. I also thank you for your expert 
guidance, assistance and support. As General Director of INS, also thank you for being 
considerate and affording me time for my academic activities.  
I would like to thank you Karolinska Institutet and UEM for the support and opportunity that you 
have given me to do this useful training that I will use to improve the lives of the Mozambican 
and global population. Here, I would like to thank, especially, Andrej Weintraub, Marita 
Wallenberg Lundgren and Arja Kramsu from Department of lab Medicine, KI.  
A special thank you INS for granting me permission for my training and supporting me when I 
had to be absent due to academic reasons.  
I thank the dedicated staff at the Maputo Central Hospital Youth Clinic and staff at the INS in 
the clinic and laboratories. Here, I especially thank my colleagues from the cell immunology lab 
of INS, namely Nádia Sitoe, Eulália Buque, Regina Machanhane, Rosa Macamo, Eduardo 
Namalango, Victoria Cumbane, Raquel Matavele and the now deceased José Matola, who all 
directly supported me.   
In addition, I would like to acknowledge Professor Gabriella Scarlatte and Monica Tolazzi from 
Department of Surgery and Molecular Genetics and Microbiology, San Raffaele Scientific 
 59 
Institute, for training me in the NAb testing, and their help with the data analysis. Thank you 
Professor Christof Geldmacher and his team from Department for Infectious Diseases & Tropical 
Medicine, University of Munich, for training me in the epitope mapping testing and their help 
with the data analysis. Thank you as well to Katarina Karlén, Teghesti Tecleab and Ass. Professor 
Charlotta Nilsson from the Public Health Agency of Sweden for training me on IFN-γ Elispot 
assay, binding antibody testing and flow cytometry analysis.  
I wish to thank Edna Viegas, my fellow PhD colleague, with whom I share authorship in two 
papers, for the teamwork. She was responsible for the clinical part of the studies. 
My sincerest thanks to Prof. Eligius Lyamuya and Prof. Gunnel Biberfeld for wonderful and 
careful coordination of the program. Additionally, I thank Prof. Gunnel Biberfeld for your input 
into the HIV incidence and TaMoVac 01 Maputo papers.  
I acknowledge Professor Eric, for the support and encouragement at the time when I initiated my 
training. Additionally, I thank you for your input into the HIV incidence and TaMoVac 01 
Maputo papers. 
Orvalho Augusto, thank you for your help with the statistics. 
Thank you the Mozambican PhD students in Sweden, especially Adolfo Condo, Juvêncio 
Manjate, Lucilio Matias, Xavier Muianga, Orlando Zacarias and Avelino Mondlane for the good 
times that we spent together. 
Thank you my friends in Mozambique, especially Gildo Muchanga, for your support. 
I specially thank my father, Paulino Tembe, mother, Adelaide Tembe, my sisters Dércia, Yolanda 
and Zelva, and my brothers Tony and Luck for your support. 
In addition, I would like to thank all others who were not mentioned but directly or indirectly 
assisted me during this journey.  
Finally, but not least, I thank my lovely wife, Celeste Tembe, and my wonderful children (Shaira, 
Yumina and Celson) for understanding my absences and giving unconditional support, so that I 
could successfully complete this training. 
 
 
 60 
9. REFERENCES 
 
1. WHO. 2016. Sexually transmitted infections. Fact sheet Available: 
http://www.who.int/ mediacentre/ factsheets/fs204/en/. 
2. WHO. 2016. HIV/AIDS. Fact sheet, p. Available: http://www.who.int/gho/hiv/en/. 
3. WHO. 2012. Global Prevalence and Incidence of Selected Curable Overview and 
Estimates. World Health Organization. Geneva, Switzerland. 
4. UNAIDS. 1998. The public health approach to STD control: UNAIDS Technical 
Update. UNAIDS Information Centre. Geneva. Switzerland. 
5. Funnye AS, Akhtar AJ, Ven D. 2003. Syphilis and Human Immunodeficiency Virus 
Co-infection. J Natl Med Assoc, Vol. 95, No. 5. 
6. Maartens G, Celum C, Lewin SR. 2014. HIV infection: epidemiology, pathogenesis, 
treatment, and prevention. Lancet, 384: 258–271. 
7. Ranjbar R, Davari A, Izadi M, Jonaidi N and Alavian SM. 2011. HIV/HBV co-
infections: epidemiology, natural history, and treatment: A review article. Iran Red 
Crescent Med J, 13(12): 855-862. 
8. Vermund SH, Tique JA, Cassell HM, Johnson ME, Ciampa PJ and Audet, CA. 
2013. Translation of biomedical prevention strategies for HIV: Prospects and 
pitfalls. J Acquir Immune Defic Syndr, 63(01): S12–S25. 
9. Cicconi P, Monforte A, Castagna A, Quirino T, Alessandrini A, Gargiulo M, 
Francisci D, et al. 2013. Inconsistent condom use among HIV-positive women in 
the “Treatment as Prevention Era”: data from the Italian DIDI study. J Int AIDS 
Soc, 16:18591. 
10. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor 
LE, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral 
microbicide, for the prevention of HIV infection in women. Science, 329(5996): 
1168–1174. 
11. Hepatitis B. WHO. 2016. Fact sheet. Available: http://www.who.int/ 
mediacentre/factsheets/ fs204/en/. 
12. Pang T. Vaccination in developing countries: problems, challenges and 
opportunities. GLOBAL PERSPECTIVES IN HEALTH - Vol. II. Available: 
http://www.eolss.net/sample-chapters/c03/e1-14-05-06.pdf.  
13. UNAIDS. 2016. Global Statistics. Fact sheet. Available: http://www.unaids. 
org/sites/default/ files/media_asset/ UNAIDS_FactSheet_en.pdf. 
 61 
14. WHO. 2016. HIV/AIDS. Global Health Observatory (GHO) data. Available: 
http://www. who. int/gho /hiv/en/. 
15. INS, INdEsI, ICF Macro. 2010. Mozambique National Survey on Prevalence, 
Behavioral Risks and Information about HIV and AIDS (2009 INSIDA) Key 
Findings.  
16. Instituto Nacional de Saúde (INS) INdEsI, Grupo Técnico Multisectorial de 
Combate ao HIV/SIDA (GTM). 2011. Vigilância Epidemiológica do HIV e seu 
Impacto Demográfico em Moçambique: Actualização, Ronda 2009. Maputo, 
Mozambique, pp. p36–40. 
17. UNAIDS. 2014. Global AIDS Response Progress Report GARPR. COUNTRY 
PROGRESS REPORT Mozambique. Available: http://www.unaids. 
org/sites/default/files/country/documents/ MOZ_narrative_report_2014.pdf. 
18. UNAIDS. 2014. Mozambique HIV Epidemic Profile., unaids.org. Available: 
http://www.unaidsrstesa.org/wp-content/uploads/2015/05/UNAids-Profile-
Mozambique.pdf. 
19. Buonaguro L, Tornesello ML, and Buonaguro FM. 2007. Human immunodeficiency 
virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and 
therapeutic implications. J Virol, pp. 10209–10219. 
20. Bila DCA, Young P, Merks H, Vubil AS, Mahomed M, Augusto A, et al. 2013. 
Evolution of primary HIV drug resistance in a subtype C dominated epidemic in 
Mozambique. PloS one.  8(7): e68213. 
21. Rubbert A, Behrenes G, et al. 2007. Pathogenesis of HIV-1 infection. 15th Edition: 
pp. 33-39 Available: www.HIVMedicine.com. 
22. Sierra S, Kupfer B and Kaiser R. 2005. Basics of the virology of HIV-1 and its 
replication. J Clin Virol, 34(4): 233-244. 
23. Sharp PM and Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring 
Harb Perspect Med, 1(1): a006841. 
24. CONSELHO DE MINISTROS - REPÚBLICA DE MOÇAMBIQUE. 2010. Plano 
Estratégico Nacional de Resposta ao HIV e SIDA, 2010 - 2014. Maputo, 
Mozambique. 
25. Buttò S, Suligoi B, Fanales-Belasio E, Raimondo M. 2010. Laboratory diagnostics 
for HIV infection. Ann Ist Super Sanità, 46(1): 24-33. 
26. Giles RE, Perry K R and Parry JV. 1999. Simple/rapid test devices for anti-HIV 
screening: do they come up to the mark? J Med Virol, 59(1): 104-109. 
 62 
27. Fearon M. 2005. The laboratory diagnosis of HIV infections. Can J Infect Dis Med 
Microbiol, 16(1): 26-30. 
28. MISAU. 2008. Guião Estratégico-Operacional para Implementação das Unidades 
de Aconselhamento e Testagem em Saúde (UATS). Maputo, Mozambique. p24-32.  
29. Ndabarora E and Mchunu G. 2014. Factors that influence utilisation of HIV/AIDS 
prevention methods among university students residing at a selected university 
campus. AHARA-J, 11(1):202-10. 
30. Gallanta M and Maticka-Tyndale E. 2004. School-based HIV prevention 
programmes for African youth. Soc Sci Med, 58(7): 1337-51. 
31. Weller SC, Davis-Beaty K. 2007. Condom effectiveness in reducing heterosexual 
HIV transmission (Review). The Cochrane Libr, 4:1-24. 
32. Beksinska ME, Smit JA, and Mantell JE. 2012. Progress and challenges to male and 
female condom use in South Africa. Sexual health, 9(1): 51-58. 
33. CDC. 2012. HIV Testing in the United States. Available: 
http://www.cdc.gov/nchhstp/newsroom/ docs/HIV-Testing-US-508.pdf. 
34. WHO. 2010. Screening donated blood for transfusion-transmissible infections: 
recommendations. World Health Organization. Geneva, Switzerland.  
35. MISAU, Instituto Nacional de Estatística (INE) e ICF International (ICFI). 2013. 
Moçambique Inquérito Demográfico e de Saúde 2011. Calverton, Maryland, USA: 
MISAU, INE e ICFI. 
36. WHO. 2013. Global update on HIV treatment: results, impact and opportunities. 
World Health Organization. Geneva, Switzerland. 
37. MISAU. 2009/2010. Guia de tratamento antiretroviral e infecções oportunistas no 
adulto, adolescente e grávida. Maputo, Mozambique. 
38. INS, UNICEF and Clinton Health access initiative. Early Infant Diagnosis of HIV 
Mozambique: progress report 2009 - 2011.  
39. UNAIDS. 2014. The Gap report. UNAIDS. Geneva, Switzerland. 
40. Barouch DH. 2008. Challenges in the development of an HIV-1 Vaccine. Nature, 
455(7213): 613–619. 
41. Koff WC. 2014. Status of HIV vaccine research & development. IAVI: Global 
Vaccine Immunization Research Forum. 
42. Letvin NL, Rao SS, Montefiori D, Seaman MS, Sun Y, Lim S-Y, et al. 2011. 
Immune and genetic correlates of vaccine protection against mucosal infection by 
SIV in monkeys. Sci Transl Med, 3: 81ra36. 
 63 
43. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. 2012. Vaccine 
protection against acquisition of neutralization-resistant SIV challenges in rhesus 
monkeys. Nature, 482: 89-93. 
44. Shiver JW, Emini EA. 2004. Recent advances in the development of HIV-1 vaccines 
using replication-incompetent adenovirus vectors. Annu Rev Med, 55: 355-372.  
45. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. 2008. 
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): 
a double-blind, randomised, placebo-controlled, test-of-concept trial. The Lancet, 
372(9653):1881-93. 
46. Freel SA, Saunders KO, and Tamaras GD. 2011. CD8+ T-cell mediated control of 
HIV and SIV infection. Immunol Res, 49(1-3): 135–146. 
47. Soghoidan DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. 
2012. HIV-specific cytolytic CD4 T cell responses during acute infection predict 
disease outcome. Sci Trans Med, 4(123): 123ra25. 
48. Robb ML, Rerks-Ngar, S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, et al. 
2012. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen 
ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 
3 efficacy trial RV 144. Lancet Infect Dis, 12(7): 531-537. 
49. Rerks-Ngarm S, Pitisutttithum P, Nitayaphan S, et al. 2009. Vaccination with 
ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med, 
361(23):2209-2220 
50. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, et al. 2009. Vaccine-
induced cellular responses control simian immunodeficiency virus replication after 
heterologous challenge. J Virol, 83(13): 6508-6521. 
51. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. 2011. Profound 
early control of highly pathogenic SIV by an effector memory T-cell vaccine. 
Nature, 473(7348): 523-527. 
52. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, et al. 2006. Preserved 
CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. 
Science, 12(5779): 1530-1533. 
53. Lisziewicz J, Calarota SA and Lori F. 2007. The potential of topical DNA vaccines 
adjuvanted by cytokines. Expert Opin Biol Ther, 7(10): 1563-74. 
54. Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, et al. 2008. Broad 
immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with 
 64 
heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis, 
198(10): 1482-1490. 
55. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, et al. 2011. Broad and potent 
immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 
recombinant MVA among healthy adults in Tanzania. Vaccine, 29(46):8417-28. 
56. Nilsson C. Godoy-Ramirez K, Hejdeman B, Brave A, Gudmundsdotter L. et al. 
2014.  Broad and potent cellular and humoral immune responses after a second late 
HIV-modified vaccinia virus Ankara vaccination in HIV-DNA-primed and HIV-
modified vaccinia virus Ankara-boosted Swedish vaccines. AIDS Res Hum Retrov, 
30(3): 299-311.  
57. Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, et al. 2015. Potent 
Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with 
Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. PLoS one, 
10(4): e0118486. 
58. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. 2010. HIV Vaccines-Lessons 
learned and the way forward. Curr Opin HIV AIDS, 5(5): 428. 
59. Kim JH, Excler JL, Michael NL. 2015.  Lessons from the RV144 Thai phase III 
HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med, 66: 
423-437. 
60. Tomaras GD, Haynes BF. 2014. Advancing toward HIV-1 vaccine efficacy through 
the intersections of immune correlates. Vaccines, 2: 15-35. 
61. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. 2012. 
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 
366(14):1275-86. 
62. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, et al. 2012.  
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that 
preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol, 
188(10): 5166-5176. 
63. Kochhar S. 2013. Challenges and impact of conducting vaccine trials in Asia and 
Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World 
Vaccine Congress, Lyon. Hum Vaccin Immunother, 9(4): 924-927. 
64. Srinivasan S. What are the challenges of conducting clinical trials for an HIV 
vaccine? Available:http://infochangeindia.org/agenda/hivaids-big-questions/what-
are-the-challenges-in-conducting-clinical-trials-for-an-hiv-vaccine.html. 
 65 
65. Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, et al. 2008. Reference 
intervals in healthy adult Ugandan blood donors and their impact on conducting 
international vaccine trials. PLoS one, 3: e3919. 
66. Omosa-Manyonyi G, Jaoko W, Anzala O, Ogutu H, Wakasiaka S, et al. 2011. 
Reasons for ineligibility in Phase 1 and 2A HIV vaccine clinical trials at Kenya Aids 
Vaccine Initiative (KAVI), Kenya. PLoS one, 6: e14580. 
67. Zeh C, Amornkul PN, Inzaule S, Ondoa P, Oyaro B, at al. 2011. Population-based 
biochemistry, immunologic and hematological reference values for adolescents and 
young adults in a rural population in western Kenya.  PLoS one, p. 6: e21040. 
68. WHO. 2012. Global incidence and prevalence of selected curable sexually 
transmitted infections - 2008. World Health Organization. Geneva, Switzerland. 
69. CDC. 2014. Morbidity and Mortality Weekly Report. MMWR, Vol. 63, No. 18.  
70. European Centre for Disease Prevention and Control – ECDC. 2012. Sexually 
transmitted infections in Europe 1990–2010. Stockholm   
71. WHO. 2011. Global HIV/AIDS response: epidemic update and health sector 
progress towards universal access: progress report 2011. World Health 
Organization. Geneva, Switzerland. 
72. WHO. 2013. Baseline report on global sexually transmitted infection surveillance 
2012. World Health Organization. Geneva, Switzerland. 
73. WHO. 2015. Sexually transmitted infections (STIs), syphilis. Availeble: 
http://gamapserver.who.int/mapLibrary/Files/Maps/gho_sti_anc_syphilis_positive.
png. 
74. Singh AE, Romanowski B. 1999, Syphilis: Review with emphasis on clinical, 
epidemiologic, and some biologic features. Clin Microbiol Rev, 12(2):187-209. 
75. LaFond RE, Lukehart SA. 2006. Biological basis for syphilis. Clin Microbiol Rev, 
19(1): 29-49. 
76. Karp G, Schlaeffer F, Jotkowitz A, Riesenberg K. 2009.  Syphilis and HIV co-
infection. Eur J Intern Med, 20(1): 9-13. 
77. Lynn WA, Lightman S. 2004. Syphilis and HIV: a dangerous combination. Lancet 
Infect Dis, 4(7): 456-66. 
78. Buchacz K, Patel P, Taylor M, Kerndt PR, Byers RH, Holmberg SD, Klausner JD. 
2004. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-
infected patients with new syphilis infections. AIDS, 18(15): 2075-2079. 
 66 
79. Kofoed K, Gerstoft J, Mathiesen LR, Benfield T. 2006. Syphilis and human 
immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-
1 viral load, and treatment response. Sex Transm Dis, 33(3): 143-148. 
80. Palacios R, Jiménez-Onate F, Aguilar M, Galindo MJ, Rivas P, et al. 2007. Impact 
of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. 
J Acquir Immune Defic Syndr, 44(3): 356-359. 
81. Manfredi R, Sabbatani S, Pocaterra D, Calza L, Chiodo F. 2006. Syphilis does not 
seem to involve virological and immunological course of concurrent HIV disease. 
AIDS, 20(2): 305-306. 
82. Chun HM, Carpenter RJ, Macalino GE, Crum-Cianflone NF. 2013. The role of 
sexually transmitted infections in HIV-1 progression: A comprehensive review of 
the literature. J Sex Transm Dis, 2013. 
83. Ratnam S. 2005. The laboratory diagnosis of syphilis. Can J Infect Dis Med 
Microbiol, 16(1): 45-51. 
84. Sato NS. 2011. Laboratorial diagnosis of syphilis - recognition, description and 
diagnosis. ISBN: 978-953-307-554-9, InTech, Available: http://www. intech 
opencom/books/syphilis-recognition-description-and-diagnosis/laboratorial-
diagnosis-of syphilis. 
85. Hou J, Liu Z, Gu F. 2005. Epidemiology and prevention of hepatitis B virus 
infection. Int J Med Sci, 2(1): 50-57. 
86. WHO. 2015. Hepatitis B in the WHO European region. World Health Organization, 
Fact sheet. Available: http://www.euro.who.int/data/assets/pdf_file/0009/ 
283356/fact-sheet-en-hep-b.pdf. 
87. Kiire CF. 1996. The epidemiology and prophylaxis of hepatitis B in sub-Saharan 
Africa: a view from tropical and subtropical Africa. Gut, pp. 38 Suppl 2:S5–S12. 
88. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. 2015. Estimations of 
worldwide prevalence of chronic hepatitis B virus infection: a systematic review of 
data published between 1965 and 2013. Lancet, 386: 1546–1555. 
89. Gudo ES, Abreu CM, Mussá T, Do Rosário Augusto Â, Otsuki K, Chambo E, 
Amade N, Tanuri A, Ferreira Jr OC, Jani IV. 2009. Serologic and molecular typing 
of human T‐lymphotropic virus among blood donors in Maputo City, Mozambique. 
Transfusion, 49(6): 1146-1150. 
 67 
90. Cunha L, Plouzeau C, Ingrand P, Gudo JPS, Ingrand I, et al. 2007. Use of 
replacement blood donors to study the epidemiology of major blood‐borne viruses 
in the general population of Maputo, Mozambique. J Med Virol, 79(12): 1832-1840. 
91. Stokx J, Gillet P, De Weggheleire A, Casas EC, Maendaenda R, et al. 2011. 
Seroprevalence of transfusion-transmissible infections and evaluation of the pre-
donation screening performance at the Provincial Hospital of Tete, Mozambique. 
BMC Infect Dis,11(1): 1. 
92. Menéndez C, Castellsagué X, Renom M, Sacarlal J, Quintó L, et al. 200. Prevalence 
and risk factors of sexually transmitted infections and cervical neoplasia in women 
from a rural area of southern Mozambique. Infect Dis Obstet Gynecol, 2010. 
93. CDC. 2005. A comprehensive immunization strategy to eliminate transmission of 
hepatitis B virus infection in the United States: recommendations of the Advisory 
Committee on Immunization Practices (ACIP). Part 1: immunization of infants, 
children, and adoles. MMWR 54(No. RR-16). 
94. Liang TJ. 2009. Hepatitis B: The Virus and Disease. Hepatology. 49(5 Suppl): S13–
S21. 
95. Di Bisceglie AM. 2009. Hepatitis B and hepatocellular carcinoma. Hepatology, 49(5 
Suppl): S56–S60. 
96. Beasley RP, Hwang LY, Lin CC and Chien CS. 1981. Hepatocellular carcinoma and 
hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet, 2(8256): 
1129-1133. 
97. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. 2002. Genetic variability in hepatitis B 
viruses. J Gen Virol, 83(6):1267-1280. 
98. Chemin I, Zoulim F. 2009. Hepatitis B virus induced hepatocellular carcinoma. 
Cancer Lett, 286(1): 52-59.  
99. Hoffmann CJ, Thio CL. 2007. Clinical implications of HIV and hepatitis B co-
infection in Asia and Africa. Lancet Infect Dis, 7(6). 
100.  Hailaye Y, Dessalegn M, Gebre-Selassie S. 2013. Hepatitis B virus co-infection: 
yet another reason for early initiation of treatment in HIV infected individuals. 
World J AIDS, 3: 313-319.  
101. Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, et al. 2002. Hepatitis B virus co-
infection in human immunodeficiency virus-infected subjects. AIDS rev, 4(1): 27-
35. 
 68 
102. Seeger C, Mason WS. 2000. Hepatitis B Virus Biology. Microbiol Mol Biol Rev, 
64(1):51-68. 
103. Lavanchy, D. 2004.  Hepatitis B virus epidemiology, disease burden, treatment, and 
current and emerging prevention and control measures. J Viral Hepat, 11(2): 97-
107. 
104. Gitlin N. 1997. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem, 
43(8):1500-1506. 
105. WHO. 2016. Immunization Coverage. Avalable: http://www.who.int/mediacentre/ 
factsheets/fs378/en/. 
106. MISAU. 2011. National Immunization Program-Comprehensive Multi-Year Plan 
(cMYP) 2012–2016. Maputo, Mozambique. 
107. CLSI. 2008. Defining, establishing, and verifying reference intervals in the clinical 
laboratory; approved guideline-Third Edition. National Committee for Clinical 
Laboratory Standards, Wayne, PA, USA, pp. C28-A3, Vol.28 No 30. 
108. Schnabl K, Chan MK, Gong Y, Adeli K. 2008.  Closing the gaps in paediatric 
reference intervals: The CALIPER Initiative. Clin Biochem Rev, (3): 89-96. 
109. Coskun A, Ceyhan E, Inal TC, Serteser M, Unsal I.  2013. The comparison of 
parametric and nonparametric bootstrap methods for reference interval computation 
in small sample size groups. Accred. Qual. Assur, 18(1): 51-60. 
110. Brave A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, et al. 2005. Multigene/ 
multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses 
by needle-free intradermal delivery. Mol Ther, 12(6): 1197-205. 
111. Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, et al. 2009. Design and 
evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine, 27(42): 5885-
95. 
112. Melo J, Folgosa E, Manjate D, Osman N, Francois I, Temmerman M, et al. 2008. 
Low prevalence of HIV and other sexually transmitted infections in young women 
attending a youth counselling service in Maputo, Mozambique. Trop Med Int 
Health, 13(1): 17-20. 
113. Barnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell ML. 2008. 
High HIV incidence in a community with high HIV prevalence in rural South 
Africa: findings from a prospective population-based study. AIDS, 22(1): 139-44. 
 69 
114. Chege W, Pals SL, McLellan-Lemal E, Shinde S, Nyambura M, Otieno FO, et al. 
2012. Baseline findings of an HIV incidence cohort study to prepare for future HIV 
prevention clinical trials in Kisumu, Kenya. J Infect Dev Ctries, 6: 870-880. 
115. Bakari M, Lyamuya E, Mugusi F, Aris E, Chale S, et al. 2000. The prevalence and 
incidence of HIV-1 infection and syphilis in a cohort of police officers in Dar es 
Salaam, Tanzania: a potential population for HIV vaccine trials. AIDS, 14(3): 313-
320. 
116. De Schacht C, Mabunda N, Ferreira OC, Ismael N, Calu N, et al. 2014. High HIV 
incidence in the postpartum period sustains vertical transmission in settings with 
generalized epidemics: a cohort study in Southern Mozambique. J Int AIDS Soc, 
17(1). 
117. Feldblum PJ, Enosse S, Dube K, Arnaldo P, Muluana C, Banze R, et al. 2014.  HIV 
prevalence and incidence in a cohort of women at higher risk for HIV acquisition in 
chokwe, southern Mozambique. PLoS one, 9: e97547. 
118. Dube K, Zango A, van de Wijgert J, Meque I, Ferro JJ, Cumbe F, et al. 2014. HIV 
incidence in a cohort o women at higher risk in Beira, Mozambique: prospective 
study 2009–2012. PloS one, 9(1): e84979. 
119. Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mlotshwa M, Madlala BT, 
et al. 2012. HIV incidence in young girls in KwaZulu-Natal, South Africa—public 
health imperative for their inclusion in HIV biomedical intervention trials. AIDS 
Behav, 16(7):1870-1876. 
120. Nel A, Mabude Z, Smit J, Kotze P, Arbuckle D, Wu J, et al. 2012. HIV incidence 
remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS 
one, 7(4): e35278. 
121. Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C, et al. 2008. 
Prevalence of infection with hepatitis B and C virus and coinfection with HIV in 
medical inpatients in Malawi. J Infect, 57(1): 72-77. 
122. Negero A, Sisay Z, Medhin G. 2011. Prevalence of Hepatitis B surface antigen 
(HBsAg) among visitors of Shashemene General Hospital voluntary counseling and 
testing center. BMC Res Notes, 4: 35. 
123. MISAU, GTM. 2013, Ronda de Vigilância Epidemiológica do HIV e Sífilis em 
Moçambique, 2011, principais resultados. Maputo, Mozambique. pp. p4–11. 
124. Carpenter LM, Kamali A, Payne M, Kiwuuwa S, Kintu P, Nakiyingi J, et al. 2002. 
Independent effects of reported sexually transmitted infections and sexual behavior 
 70 
on HIV-1 prevalence among adult women, men, and teenagers in rural Uganda. J 
Acquir Immune Defic Syndr, 29: 174-180. 
125. WHO. 2014. Global guidance on criteria and processes for validation: elimination 
of mother-to-child transmission (EMTCT) of HIV and syphilis. World Health 
Organization. Geneva, Switzerland. 
126. Okafor GO, Obi GO, Chukwudebelu WO. 1979. The incidence of hepatitis B 
surface antigen in Nigeria. Trans R Soc Trop Med Hyg, 73(6): 648-650. 
127. Beasley RP, Lin CC, Hwang LY, Chien CS. 1981. Hepatocellular carcinoma and 
hepatitis B virus: a prospective study of 22 707 men in Taiwan. The Lancet, 
318(8256): 1129-1133. 
128. Abdool Karim SS, Thejpal R, Singh B. 1989. High prevalence of hepatitis B virus 
infection in rural black adults in Mseleni, South Africa. Am J Public Health, 79(7): 
893-894. 
129. Pellizzer G, Ble C, Zarnperetti N, Stroffolini T, Upunda G, Rapicetta M, Chionne 
P, Villano U, Fabris P; de Lalla, F. 1994. Serological survey of hepatitis B infection 
in Tanzania. Public Health, 108(6): 427-431. 
130. Noubiap JJN, Nansseu JRN, Ndoula ST, Bigna JJR, Jingi AM, Fokom-Domgue J. 
2015. Prevalence, infectivity and correlates of hepatitis B virus infection among 
pregnant women in a rural district of the Far North Region of Cameroon. BMC 
public health, 15(1): 1. 
131. Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Sateren WB, et al. 2008. Reference 
ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. 
PloS one, 3(10): e3327. 
132. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, et al. 2004. Population-
based hematologic and immunologic reference values for a healthy Ugandan 
population. Clin Diagn Lab Immunol, 11: 29–34. 
133. Maini MK, Gilson RJ, Chavda N, Gill S, Fakoya A, et al. 1996. Reference ranges 
and sources of variability of CD4 counts in HIV-seronegative women and men. 
Genitourin Med, 72: 27-31. 
134. Rudy BJ, Wilson CM, Durako S, Moscicki AB, Muenz L, et al. 2002. Peripheral 
blood lymphocyte subsets in adolescents: a longitudinal analysis from the REACH 
project. Clin Diagn Lab Immunol, 9: 959-965. 
135. Urassa WK, Mbena EM, Swai AB, Gaines H, Mhalu FS, et al. 2003. Lymphocyte 
subset enumeration in HIV seronegative and HIV-1 seropositive adults in Dar es 
 71 
Salaam, Tanzania: determination of reference values in males and females and 
comparison of two flow cytometric methods. J Immunol Methods, 277: 65-74. 
136. Oladepo DK, Idigbe EO, Audu RA, Inyang US, Imade GE, et al. 2009. 
Establishment of reference values of CD4 and CD8 lymphocyte subsets in healthy 
Nigerian adults. Clin Vaccine Immunol, 16: 1374-1377. 
137. Augusto G, Nalá R, Casmo V, Sabonete A, Mapaco L, Monteiro J . 2009. 
Geographic distribution and prevalence of Schistosomiasis and soil-transmitted 
helminthes among schoolchildren in Mozambique. Am J Trop Med Hyg, 81: 799-
803.  
138. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, et al. 1999. 
Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab 
Immunol, 6: 410-414. 
139. Omosa-Manyonyi G, Jaoko W, Anzala O, Ogutu H, Wakasiaka S, et al. 2011. 
Reasons for ineligibility in Phase 1 and 2A HIV vaccine clinical trials at Kenya Aids 
Vaccine Initiative (KAVI), Kenya. PloS one, 6(1): e14580. 
140. Munseri PJ, Kroidl A, Nilsson C, Geldmacher C, Mann P, et al. 2015. Priming with 
a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with 
recombinant HIV-1 MVA vaccine is safe and immunogenic: A phase IIa 
randomized clinical trial. PloS one, 10(4): e0119629. 
141. Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, et al. 2013. Safety and 
immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost 
regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. PLoS 
one, 8(2): e55831. 
142. Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, et al. 2009. 
Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed 
HIV-specific immune responses in humans despite pre-existing vaccinia immunity. 
Vaccine, 27(33): 4468-4474. 
143. Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, et al. 2015. HIV-
DNA given with or without intradermal electroporation is safe and highly 
immunogenic in healthy Swedish HIV-1 DNA/MVA vaccinees: A phase I 
randomized trial. PloS one, 10(6): e0131748. 
144. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. 2010. Phase I safety 
and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant 
modified vaccinia Ankara-HIV-1 vaccine candidate. PloS one, 5(11): e13983.
 73 
 
 
 
 
 
 
 
 
 
 
 
